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THE	MERGING	OF	TWO	PATHWAYS	IN	PARKINSON’S	DISEASE		
CHELSEA	BRAIS	TRENGROVE			Boston	University	School	of	Medicine,	2016	Major	Professor:	Benjamin	Wolozin,	M.D.,	Ph.D.,	Professor	of	Pharmacology	and												Neurology	 	ABSTRACT	Autophagy	is	compromised	in	Parkinson’s	disease	(PD)	with	a	number	of	PD-associated	genetic	mutations	leading	to	its	dysregulation.	Leucine-rich	repeat	kinase	(LRRK2)	mutations,	causative	of	PD,	aberrantly	enhance	autophagy.	Our	lab	elucidated	a	LRRK2	gene	regulatory	network	identifying	transcripts	showing	coordinated	expression	level	changes	associated	with	PD.	Histone	deacetylase	6	(HDAC6)	was	found	to	be	an	important	interactor	with	LRRK2,	regulating	many	of	the	same	transcripts.	The	majority	of	these	transcripts	associate	with	autophagy	and	the	lysosomal	complex.	I	hypothesized	that	LRRK2	interacts	with	HDAC6	to	regulate	autophagy.	Silencing	of	HDAC6	in	SH-SY5Y	normalized	the	autophagosomal	size	altered	by	expression	of	PD-linked	LRRK2	mutants.	This	work	identified	a	key	role	for	HDAC6	in	mediating	the	autophagic	dysfunction	induced	by	the	mutant	LRRK2.	In	addition	to	autophagy,	stress	granule	(SG)	formation	has	emerged	as	a	compelling	mechanism	in	the	pathogenesis	of	PD.	RNA-binding	proteins	(RBPs),	
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such	as	T-cell	intracellular	antigen-1	(TIA-1),	are	major	component	of	SGs.	I	observed	TIA-1	translocating	from	the	nucleus	to	the	cytoplasm	in	PD	cortex	without	forming	SGs.	Hu	antigen	D	(HuD)	also	showed	changes,	with	the	RBP	more	present	in	the	cytoplasm	than	the	nucleus	in	PD	with	no	SGs	observed.	These	preliminary	studies	lead	to	the	hypothesis	that	low	levels	of	SGs	result	from	an	inhibition	by	alpha-synuclein	(αsyn),	or	hyperactive	autophagy.	For	that	purpose,	brain	tissues	from	a	mouse	model	of	PD	(A53T-αsyn	transgenic	mouse)	were	examined	by	immunohistochemistry.	There	was	no	difference	in	TIA-1	expression	in	control	and	A53T-αsyn	expressing	mouse	brains,	or	SG	formation	in	primary	neurons	after	treatment	with	recombinant	A53T	fibrils.	To	determine	whether	the	lack	of	SGs	in	PD	brain	was	due	to	activation	of	autophagy,	BE-M17	cells	were	treated	with	rapamycin,	an	autophagy	activator,	which	decreased	SGs	by	50%.	Overexpression	of	TIA-1	in	BE-M17	cells	under	arsenite	treatment	also	increased	autophagosomal	size	by	50%,	indicating	co-regulation	of	SGs	and	autophagy.	My	work	indicates	that	the	pathophysiology	of	PD	is	associated	with	a	loss	of	SGs	due	to	elevated	activity	of	autophagy,	presumably	due	to	PD-linked	LRRK2	mutations.	This	co-regulatory	network	may	be	a	potential	therapeutic	target	of	PD.		 	
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CHAPTER	ONE	–	INTRODUCTION:	AN	OVERVIEW	OF	PARKINSON’S	DIESEASE	
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Demographics	and	symptoms	PD,	first	characterized	by	James	Parkinson	in	1817,	is	a	devastating	neurodegenerative	disease	effecting	millions	of	people	world-wide.	It	is	the	most	prevalent	neurodegenerative	disease	after	Alzheimer’s	disease	(AD),	and	the	most	predominant	neurodegenerative	disease	of	movement,	with	health	care	costs	exceeding	$14	billion	a	year	in	the	US	alone	(Kowal	et	al.,	2013).	On	the	physical	level,	it	is	defined	by	distinct	motor	symptoms	including	resting	tremor,	rigidity,	stiffness,	bradykinesia	(slowed	movement)	and	postural	instability.	As	the	disease	progresses,	people	may	observe	cognitive	defects	including	depression,	slurred	speech,	fatigue	and	even	dementia.	Approximately	1-2%	of	the	population	over	the	age	of	65	acquire	PD,	although	symptoms	and	the	age	of	onset	are	varied	(Goedert,	2001).	The	average-age	of	onset	is	approximately	60.	Early-onset	cases,	while	rare,	are	also	reported,	and	include	individuals	under	the	age	of	50.	They	tend	to	have	a	higher	rate	of	genetic	factors	that	trigger	the	disease.		
Therapeutics	PD	remains	incurable,	but	there	are	effective	drugs	and	treatments	that	combat	the	amassment	of	symptoms.	PD	therapeutics	have	greatly	improved	the	quality	of	life	for	people	with	PD.	In	the	early	stages	of	the	disease,	if	tremor	is	the	only	presenting	symptom,	patients	may	take	an	anticholinergic	to	block	nerve	impulses	(Katzenschlager	et	al.,	2012).	Individuals	may	also	undergo	physical,	speech,	swallowing	and	psychological	therapy;	and	are	directed	towards	a	healthy	
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diet	with	lots	of	exercise.	A	meta-analysis	from	2008	on	the	effects	of	exercise	in	PD	shows	a	significant,	positive	correlation	between	exercise	and	improved	physical	functioning,	leg	strength,	balance	and	walking	(Goodwin	et	al.,	2008).	While	these	therapies	are	important	in	maintaining	a	healthy,	functional	life-style,	drugs	are	the	first	defense	against	PD	progression.		The	most	commonly	prescribed	and	well	known	of	these	drugs	is	levodopa.	Levodopa	(or	L-DOPA)	is	a	dopamine	precursor.	It	is	able	to	pass	the	blood	brain	barrier,	where	it	is	converted	into	dopamine	via	the	enzyme,	DOPA	decarboxylase.	Therein,	levodopa	works	by	replenishing	dopamine	that	dying	substantia	nigra	pars	compacta	(SNpc)	neurons	are	no	longer	adequately	producing.	First	tested	on	PD	patients	in	1961,	a	dramatic	decrease	in	rigidity	and	bradykinesia	was	seen	in	the	following	years	(Tolosa	et	al.,	1998).	With	these	improvements	came	equally	evident	side	effects.	Patients,	to	this	day,	experience	dyskinesias	(or	the	inability	to	control	movements)	along	with	a	magnitude	of	other	side	effects	that	become	increasingly	apparent	with	the	duration	of	use.	Pharmaceutical	companies	continue	to	focus	on	ways	to	improve	levodopa.	The	problem	with	levodopa	arises,	not	only	from	the	side	effects,	but	also	from	the	“wearing-off”	effect	of	the	drug,	in	which	less	dopamine	neurons	result	in	reduced	dopamine	uptake	and	buffering	(Brooks,	2008).	With	less	dopamine	neurons	to	buffer	the	amount	of	dopamine	in	the	synapses,	the	effectiveness	of	levodopa	can	drop	sharply	at	the	end	of	each	dose.	A	dose	of	levodopa	may	last	only	an	hour.	This	decreased	effectiveness	can	lead	to	serious	motor	control	problems,	i.e.,	severe	fluctuations	between	dyskinesia	and	
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immobility,	with	patients	reverting	to	taking	multiple	crushed	up	pills	a	day	(Müller	et	al.,	1999).	Since	levodopa	works	so	well	in	the	early	stages,	companies	have	focused	on	improving	the	deliverance	of	levodopa	to	the	brain,	as	opposed	to	making	an	entirely	new	drug.	In	the	early	1970s,	carbidopa	was	designed,	and	given	concomitantly	with	levodopa.	Carbidopa	is	a	competitive	inhibitor	of	DOPA	decarboxylase,	the	enzyme	that	converts	levodopa	into	dopamine.	It	almost	doubles	the	plasma	half-life	of	levodopa.	This	means	that	3%	of	a	levodopa	dose	gets	to	the	brain,	as	apposed	to	1%	when	levodopa	is	given	alone.	Conveniently,	carbidopa	is	unable	to	pass	the	blood	brain	barrier,	so	it	only	inhibits	the	conversion	of	L-DOPA	to	dopamine	in	the	peripheral	nervous	system	(PNS).	This	greatly	decreases	many	of	the	peripheral	and	heart-associated	side	effects	of	levodopa,	since	it	prevents	an	abundance	of	dopamine	in	the	PNS.	Patients	notably	experience	less	nausea	and	vomiting	due	to	a	decreased	activation	of	chemoreceptors	at	the	area	postrema,	located	on	the	brain	stem	outside	the	blood	brain	barrier	(Tolosa	et	al.,	1998).	Other	important	advantages	of	a	carbidopa/levodopa	dose	include	quicker	induction,	diurnal	symptom	control	and	reduced	levodopa	dose	requirements.	This	mixture	is	sold	most	popularly	under	the	brand	name	Sinemet.	In	the	late	1980s,	Sinemet	CR	(controlled	release)	was	released.	This	slow	release	carbidopa/levodopa	mix	elevates	plasma	levels	3-4	hours	longer	than	standard	Sinemet,	and	diminishes	early	morning	dystonia	and	disrupted	sleep	patterns	(Tolosa	et	al.,	1998).	
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Other	peripheral	enzyme	inhibitors	that	support	the	effectiveness	of	levodopa	include	monoamine	oxidase	inhibitors	(MAOIs)	and	catechol-O-methyltransferase	inhibitors	(COMT-Is).	Also	introduced	in	the	1960s	for	use	in	PD,	MAOIs	prevent	the	breakdown	of	monoamines	like	dopamine.	Selegiline	and	rasagiline,	the	two	most	common	MAOIs	in	the	treatment	of	PD,	preferentially	and	irreversibly	inhibit	MAO-B.	Although	both	MAO-A	and	MAO-B	break	down	dopamine,	MAO-B	works	more	specifically	on	dopamine,	while	MAO-A	breaks	down	a	number	of	other	neurotransmitters.	This	effectively	increases	the	efficacy	and	longevity	of	levodopa	in	the	body.	One	study	tracking	44	patients	taking	either	selegiline	or	placebo	found	that	selegiline	dramatically	decreased	the	rate	at	which	PD	symptoms	presented	(Riederer	et	al.,	2003).	And	the	Deprenyl	And	Tocopherol	Antioxidative	Therapy	Of	Parkinsonism	(DATATOP)	study,	spanning	over	50	years	and	800	patients,	found	that	selegiline	significantly	delayed	the	need	for	levodopa	by	about	9	months	(Shoulson	et	al.,	1998).	The	COMT-Is,	first	introduced	for	PD	in	the	1990s,	also	prevents	the	breakdown	or	inactivation	of	dopamine.	COMTs	act	by	expediting	the	donation	of	a	methyl	group	to	a	catecholamine.	This	means	COMTs	can	inactivate	both	L-DOPA	and	dopamine.	Entacapone	and	tolcapone	are	the	choice	COMT-Is.	Entacapone	is	unable	to	penetrate	the	blood	brain	barrier.	It	acts	by	inhibiting	the	conversion	of	L-DOPA	to	3-O-Methyldopa,	a	substance	that	is	also	blood	brain	barrier	impenetrable.	Therein,	entacapone	allows	more	L-DOPA	to	reach	the	central	nervous	system	(CNS)	by	blocking	this	conversion.	Tolcapone	is	blood	brain	barrier	penetrable.	This	allows	it,	not	only	to	block	the	conversion	of	L-
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DOPA	in	the	PNS,	but	also	in	the	CNS	as	well	as	the	conversion	of	dopamine	in	both	areas.	A	study	by	Albany	Medical	Center	found,	when	comparing	entacapone	and	tolcapone,	that	tolcapone	causes	levodopa	to	have	a	longer	and	greater	efficacy	(Factor	et	al.,	2001).	However,	entacapone	is	still	widely	used	due	to	the	hepatic	toxicity	associated	with	tolcapone.	In	2003,	the	Food	and	Drug	Administration	approved	Stalevo,	an	entacapone,	carbidopa,	and	levodopa	mix.	The	FIRST-STEP	study,	completed	in	2007,	shows	improved	daily	living	and	motor	function	when	compared	to	levodopa	and	carbidopa	alone	(Hauser	et	al.,	2009).	A	mixture	of	a	COMT-I,	carbidopa	and	levodopa	seems	to	be	the	best	option	for	most	PD	patients	at	present.		Levodopa	and	its	cohorts,	while	the	standard	of	care,	are	not	the	only	form	of	care.	Dopamine	agonists	were	developed	in	the	1970s	as	an	alternative	to	levodopa.	Bromocriptine,	the	first	agonist	found	to	be	effective,	selectively	binds	the	D2	receptor	along	with	a	few	serotonin	receptors.	This	is	important	for	its	effects	since	D1	agonists	are	shown	to	have	little	benefit	in	PD.	D2	receptors	are	active	in	the	indirect	pathway	of	the	SNpc.	Bromocriptine	reduces	many	of	the	motor	symptoms	associated	with	PD,	but	there	is	a	high	incidence	of	adverse	effects,	most	notably,	nausea	and	headaches.	And	like	all	other	dopamine	agonists,	bromocriptine	can	lead	to	schizophrenia-like	symptoms,	such	as	hallucinations	and	confusion.	However,	the	14-year	PD	Reasearch	Group	United	Kingdom	trial	ultimately	found	that	levodopa	therapy	produced	better	scores	on	the	Webster	scale,	a	scale	used	for	quantifying	motor	symptoms	in	PD	(Katzenschlager	et	al.,	2008).	Apomorphine	was	the	first	
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synthesized	dopamine	agonist.	It	non-selectively	binds	the	D1	and	D2	dopamine	receptors.	It	binds	the	D2	receptor	an	order	of	magnitude	greater	than	the	D1	receptor.	While	apomorphine	causes	a	reduced	need	for	levodopa,	and	a	profound	decrease	in	motor	symptoms,	it	can	only	be	intermittently	injected	subcutaneously,	and	has	a	very	short	half-life.	It	is	commonly	used	to	manage	sudden,	rigid	“off”	states	associated	with	the	time	between	levodopa	doses	(Radad	et	al.,	2005).	Ropinirole,	pramipexole	and	rotigotine	act	clinically	as	D2	receptor	agonists,	but	also	have	slight	D3	receptor	activity	(Reichmann	et	al.,	2006).	This	can	cause	other	adverse	symptoms	such	as	compulsive	gambling	and	hypersexuality	(Reichmann	et	al.,	2006).	Rotigotine	is	unique	in	that	it	is	given	as	a	once-daily	transdermal	patch,	and	has	been	shown	to	have	similary	efficacy	and	tolerability	to	pramipexole	(Chen	et	al.,	2009,	Reichmann	et	al.,	2006).		While,	there	are	a	number	of	exceedingly	beneficial	drugs	in	the	treatment	of	the	symptoms	of	PD,	many	of	them	hold	equally	devastating	side	effects.		PD	patients	who	are	unresponsive	to	pharmaceuticals,	or	who	have	severe	dyskinesia	can	undergo	deep	brain	stimulation,	an	invasive,	surgical	procedure	in	which	a	pacemaker-like	pulse	generator	is	placed	in	the	globus	pallidus	or	the	subthalamic	nucleus.	This	is	a	well	established	procedure	that	decreases	the	frequency	of	dyskinesia,	sometimes	ablating	it,	while	also	diminishing	the	dose	of	pharmaceuticals	necessary	to	modulate	PD	symptoms	(Li	et	al.,	2014,	Rascol	et	al.,	2011).	However,	numerous	studies	have	shown	deep	brain	stimulation	is	associated	
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with	a	number	of	other	side	effects,	as	well	as	an	increased	risk	of	adverse	events	including	brain	hemorrhage	and	infection	(Gever	et	al.,	2011).		Therapeutics	for	PD	have	significantly	improved	the	management	of	symptoms	of	the	disease,	but	these	reliefs	are	temporary	and	offer	no	halt	to	degeneration.	αsyn	antibodies	have	recently	been	developed	by	a	number	of	biotechnology	companies	that	show	promising	signs	of	safety	in	humans	in	phase	I	clinical	trials	(Rodgers	et	al.,	2015).	Monoclonal	antibodies	that	clear	fibrils	of	αsyn	have	been	shown	to	lower	dopamine	neuron	degeneration	in	mice	(Tran	et	al.,	2014).	Genetic	manipulation	through	viral	delivery	is	another	avenue	of	study	that	could	transform	the	field.	These	lentiviruses	would	modulate	neurotrophic	factors,	autophagic	pathways	or	microRNA	expression	levels	(Berry	et	al.	2011).	Unfortunately,	this	field	is	far	from	reaching	efficacy	in	humans.	Instead	of	focusing	solely	on	the	dopamine	pathway,	drugs	targeting	specific	deregulated	pathways	in	PD	to	halt	or	reverse	the	progression	of	the	disease	should	be	the	vein	of	study	in	the	field.		
Prognosis	Progression	of	the	disease	is	different	for	every	person,	but	without	treatment	the	disease	usually	advances	rapidly	in	the	early	stages,	and	slows	down	in	the	later	stages.	Individuals	can	become	bedridden	in	as	early	as	ten	years.		Fortunately,	most	people	are	treated	and	studies	have	shown	that	some	individuals	have	avoided	motor	symptoms	for	up	to	40	years	(Poewe	et	al.,	2006).	
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From	the	onset	of	motor	symptoms,	patients	on	average	live	more	than	15	years.	Proper	treatment	of	motor	as	well	as	cognitive	symptoms	may	increase	individuals’	lifespan.	
	
Neuropathology	90%	of	PD	cases	are	sporadic,	while	the	other	10%	are	familial	cases	related	to	specific	mutations.	Even	though	the	genetics	of	PD	varies	between	these	two	cases,	they	both	converge	on	similar	molecular	dysfunctions.	Beginning	in	the	dorsal	1X/X	motor	nucleus,	PD	degeneration	progresses	up	the	brain	stem	to	the	SNpc	where	classic	PD	symptoms	originate	from	loss	of	dopamine	neurons	(Pan	et	al.,	2008).	Surviving	neurons	contain	dense	inclusions	of	Lewy	bodies	(or	Lewy	neurites)	filled	with	aggregated	alpha-synuclein	(αsyn).	Tau,	a	microtubule-associated	protein	that	regulates	microtubule	dynamics,	may	also	form	fibrils	that	associate	with	Lewy	bodies	(Nonaka	et	al.,	2011).	Also	associated	with	the	manifestation	of	PD	are	dysfunctional	mitochondria,	oxidative	stress,	and	a	dysfunctional	autophagy	and	ubiquitin-proteasome	system	(UPS).			
Neuro	tract	In	a	normally	functioning	brain	the	SNpc	inhibits	the	striatum	(putamen)	via	dopamine	binding	D2	receptors.	The	striatum	then	inhibits	the	globus	pallidus	(external)	with	GABA.	This,	in	turn,	inhibits	the	subthalamic	nucleus	with	GABA,	which	activates	the	globus	pallidus	(internal)	with	glutamate.	This,	finally,	inhibits	
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the	thalamus	with	GABA,	which	excites	the	motor	cortex.	In	PD,	the	SNpc	is	unable	to	inhibit	the	striatum	through	this	pathway,	and	the	motor	cortex	is	not	activated.	It	is	this	lack	of	activation	that	causes	many	of	the	motor	and	rigidity	symptoms	associated	with	PD.		
Genetics	Many	genetic	mutations	are	linked	with	PD	and	lead	to	sporadic	and	familial	PD.	These	include	mutations	in	SNCA	(αsyn),	LRRK2,	UCH-L1	(ubiquitin	carboxy-terminal	hydrolase	L1),	ATP13A2	(ATPase	Type	13A2),	GBA	(glucocerebrosidase),	
DJ-1	(protein	deglycase),	PINK1	(PTEN-induced	putative	kinase	1),	and	PARK2	(Parkin).	Below	is	a	table	of	known	genes	linked	to	or	associated	with	PD	(Table	1.1)	
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	Table	1.1.	Known	genes	linked	or	associated	with	PD	(adapted	from	PDgene.org	and	genenames.org).			 	
PARK
Inheritance
Pattern Approved	Symbol ProteinPARK1	(PARK4) Dominant SNCA Synuclein	alphaPARK2 Recessive PARK2 Parkin	RBR	E3	ubiquitin	protein	ligasePARK3 Dominant PARK3 Parkinson	disease	3	(autosomal	dominant,	Lewy	body)PARK5 Dominant UCHL1 Ubiquitin	C-terminal	hydrolase	L1PARK6 Recessive PINK1 PTEN	induced	putative	kinase	1PARK7 Recessive PARK7 Parkinson	protein	7PARK8 Dominant LRRK2 Leucine-rich	repeat	kinase	2PARK9 Recessive ATP13A2 ATPase	type	13A2PARK10 Dominant PARK10 Parkinson	disease	10	(susceptibility)PARK11 Dominant PARK11 Parkinson	disease	11	(autosomal	recessive,	early	onset)PARK12 X-linked PARK12 Parkinson	disease	12	(susceptibility)PARK13 Dominant HTRA2 HtrA	serine	peptidase	2PARK14 Recessive PLA2G6 Phospholipase	A2	group	VIPARK15 Recessive FBXO7 F-box	protein	7PARK16 Dominant PARK16 Parkinson	disease	16	(susceptibility)PARK17 Dominant VPS35 VPS35	retromer	complex	componentPARK18 Dominant EIF4G1 Eukaryotic	translation	initiation	factor	4	gamma,	1MAPT Microtubule-associated	protein	tauTMEM175 Endosomal/lysomomal	potassium	channel	TMEM175ASH1L Histone-lysine	N-methyltransferase	ASH1LMCCC1 Methylcrotonoyl-CoA	carboxylase	subunit	alpha,	mitochondrialSTK39 STE20/SPS1-related	proline-alanine-rich	protein	kinaseIntergenicBST1 ADP-ribosyl	cyclase/cyclic	ADP-ribose	hydrolase	2NUCKS1 Nuclear	ubiquitous	casein	and	cyclin-dependent	kinase	substrate	1TMEM229B Transmembrane	protein	229BGPNMB Glycoprotein	(Transmembrane)	NMBHLA-DQB1 HLA	class	II	histocompatibility	antigen,	DQ	beta	1	chainIntergenicBCKDK [3-methyl-2-oxobutanoate	dehydrogenase	[lipoamide]]	kinase,	mitochondrialMIR4697 microRNA	4697INPP5F Phosphatidylinositide	phosphatase	SAC2FAM47E Family	with	sequence	similarity	47	member	ERIT2 GTP-binding	protein	Rit2CCDC62 Coiled-coil	domain-containing	protein	62GCH1 GTP	cyclohydrolase	1SIPA1L2 Signal-induced	proliferation-associated	1-like	protein	2UBOX5 U-box	domain-containing	protein	5TMPRSS9 Transmembrane	protease	serine	9DLG2 Disks	large	homolog	2IntergenicHUD Hu-antigen	DGBA GlucosylceramidaseMT-TT Mitochondrially	encoded	tRNA	threonine
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The	UCH-L1	and	ATP13A2	mutations	play	a	role	protein	degradation.	UCH-LI	is	a	neuron	specific	deubiquitinating	enzyme,	and	is	thought	to	maintain	ubiquitin	homeostasis	in	neurons	by	stabilizing	ubiquitin	monomers	(Osaka	et	al.,	2003).	Scientists	speculate	that	the	I93M	loss	of	function	mutation	impairs	the	UPS	by	reducing	the	amount	of	ubiquitin	monomers	in	the	cytosol,	this	in	turn	leading	to	harmful	protein	aggregation	since	proteins	are	not	being	targeted	to	the	proteasome	(Kowalski	et	al.,	2012).	ATP13A2	is	a	transmembrane	lysosomal	P-type	ATPase	that	is	active	in	the	transport	of	cations	across	the	lysosomal	membrane	(Yang	et	al.,	2007,	Tan	et	al.,	2001).	Loss	of	function	mutations	in	this	protein	leads	to	lysosomal	dysfunction,	this,	again,	leading	to	insufficient	protein	degradation	and	an	increase	in	unwanted	proteins	(Yang	et	al.,	2007).	Mutations	in	GBA	are	associated	with	Gaucher’s	disease,	a	lysosmal	storage	disorder.	Heterozygous	mutations	in	the	gene	are	correlated	with	PD	and	also	lead	to	lysosomal	dysfunction	((Irwin	et	al.,	2014,	Dehay	et	al.,	2013).		Parkin	and	PINK1,	integral	proteins	in	mitochondrial	health	and	regulation,	are	correlated	with	autosomal	recessive	PD,	as	is	the	redox	sensitive	DJ1	protein	(Canet-Aviles	et	al.,	2004).	The	role	of	DJ-1	is	unclear,	but	mutations	in	its	gene	contribute	to	early-onset	PD.	It	appears	to	function	as	a	sensor	or	scavenger	for	oxidative	stress,	localizing	to	the	mitochondria	to	fulfill	a	possible	protective	mechanism,	as	well	as	functioning	as	a	regulator	of	the	20S	proteasome	(Canet-Aviles	et	al.,	2004,	Moscovitz	et	al.,	2015).	PINK1	and	Parkin	are	integral	for	mitochondrial	health	and	mitophagy.	PINK1	phosphorylates	and	recruits	Parkin,	an	
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E3	ubiquitin	ligase,	to	the	mitochondria	where	it	ubiquitinates	mitochondrial	products	and	damaged	mitochondria	for	degradation	(Koyano	et	al.,	2014).	PINK1	is	also	thought	to	be	a	calcium-sensing	kinase	with	a	mitochondrial	targeting	sequence	that	regulates	calcium	efflux	from	the	mitochondria	via	the	Na+/Ca2+	exchanger	(Gandi	et	al.,	2007).	Loss	of	PINK1	function	therein	leading	to	the	production	of	ROS	and	impaired	respiration,	which	leads	to	the	opening	of	the	mitochondrial	permeability	transition	pore	and	the	release	of	caspases	(Gandi	et	al.,	2007).				
Alpha-synuclein	Present	in	sporadic	and	familial	PD,	αsyn	is	a	small	140	amino	acid	protein	encoded	by	the	SNCA	gene	that	makes	up	up	to	1%	of	all	soluble	cytosolic	protein	in	brain	fractions	(Clayton	et	al.,	1999).	Especially	enriched	in	neural	tissue,	and	endogenously	localized	in	nerve	terminals,	the	role	of	αsyn	remains	unknown,	but	studies	suggest	it	plays	a	role	in	synaptic	vesicle	recycling	(Goedert	et	al.,	2001,	Chu	et	al.,	2011).	And	numerous	studies	have	found	that	overexpression	of	the	gene	leads	to	dopamine	neuronal	death	(Giasson	et	al.,	2002,	Tsika	et	al.,	2010,	Chu	et	al.,	2011).		αsyn	inclusions	are	a	hallmark	of	PD.	These	small	proteins	fibrillize	to	form	the	bulk	of	Lewy	bodies	(Volpicelli-Daley	et	al.,	2014).	There	are	several	mutations	associated	with	familial	PD	including	the	A53T,	A30P	and	E46K	mutations.	These	three	dominant	mutations	in	PD	lead	to	early	onset	of	the	disease,	and	are	associated	with	enhanced	fibrillization	(Tsika	et	al.,	2010).		The	A53T	mutation	
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fibrillizes	especially	rapidly	when	compared	to	wild	type	(WT)	αsyn	and	other	mutations	(Kotzbauer	et	al.,	2004).	Overexpression	of	WT	and	mutant	αsyn	in	mouse	models	can	seed	fibril	formation	and	neurodegeneration	but	these	effects	are	area	and	concentration	dependent	with	some	groups	debating	the	relatedness	to	PD	(Giasson	et	al.,	2002,	Lee	et	al.,	2004,	Tsika	et	al.,	2010).		Like	amyloid	beta,	the	protein	amassment	in	AD	plaques,	the	field	is	split	on	whether	αsyn	oligomers	or	fibrils	are	the	toxic	species	in	PD	(Winner	et	al.,	2011).	However,	most	groups	have	found	the	oligomers	to	be	the	toxic	species	(Goedert	et	al.,	2001,	Lee	et	al.,	2004,	Winner	et	al.,	2011).	αsyn	is	a	natively	unfolded	protein	that	forms	alpha	helices	in	the	presence	of	acidic	phospholipids	(Clayton	et	al.,	1999).	The	monomer	formation	into	oligomers	is	concentration	dependent	and	occurs	via	a	polymerization	step	(Tsika	et	al.,	2010).	These	oligomers	are	then	nucleated	into	protofibrils	and	fibrils	in	which	αsyn	takes	on	a	highly	beta-sheet	rich	conformation	(Lee	et	al.,	2004).	These	fibrils	compact	into	pale	bodies	in	the	cytoplasm	where	they	eventually	aggregate	into	Lewy	bodies	(Wakabayashi	et	al.,	2007).	The	standard	for	inducing	PD-like	neurodegeneration	with	αsyn	has	become	the	use	of	pre-formed	αsyn	fibrils	which	seed	serpentine-like	fibrils	throughout	the	brain	(Volpicelli-Daley	et	al.,	2011).	These	fibrils	are	formed	in	vitro	over	the	course	of	a	week	via	shaking	at	room	temperature.	The	toxicity	of	these	fibrils	is	initiated	by	sonication	of	the	fibrils	into	smaller	fibrils.	These	can	be	used	in	primary	culture	or	injected	into	mouse	brains	(Winner	et	al.,	2011,	Kotzbauer	et	al.,	2004).	While	the	literature	agrees	that	oligomers	and	protofibrils	are	the	more	toxic	species,	they	do	
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not	readily	seed	fibrillization	in	culture	or	brain	(Luk	et	al.,	2009).	Treatment	with	αsyn	fibrils	leads	to	prion-like	seeding	throughout	the	culture	or	brain,	which	is	why	it	is	recommended	to	work	with	these	fibrils	at	a	biosafety	level	2	(BSL	2)	(Volpicelli-Daley	et	al.,	2011,	Irwin	et	al.,	2013).			
Leucine-rich	repeat	kinase	2	
LRRK2	mutations	are	the	most	common	familial	PD	mutations	leading	to	late-onset	autosomal	dominant	PD	(Zimprich	et	al.,	2004,	Paisán-Ruıź	et	al.,	2004,	Boon	et	al.,	2014).	It	was	discovered	separately	by	two	groups	to	be	linked	to	familial	PD	in	2004	(Paisán-Ruıź	et	al.,	2004,	Zimprich	et	al.,	2004).	Due	to	its	high	penetrance	and	presence,	LRRK2	is	a	primary	target	for	understanding	the	mechanisms	of	PD,	as	well	as	a	potential	target	for	regulation	of	the	disease.	WT	LRRK2	is	self-regulating	and	contributes	to	a	number	of	cellular	functions	including	roles	in	protein	scaffolding,	translation,	neurite	outgrowth	(Tong	et	al.,	2012).	Studies	have	shown	a	wide	range	of	LRRK2	activities	including	vesicular	dynamics,	mitogen-activated	protein	kinases	(MAPK)	interactions	and	microRNA	translational	repression	(Xiong	et	al.,	2010,	Bravo-San	Pedro	et	al.,	2012,	Gehrke	et	al.,	2010).	Many	cell	biologists	are	now	looking	at	LRRK2	as	a	key	mediator	of	autophagy	(Plowey	et	al.,	2008,	Tsika	et	al.,	2012,	Alegre-Abarrategui	et	al.,	2009,	Bravo-San	Pedro	et	al.,	2012).			LRRK2	is	a	large	multisubunit	protein	spanning	2527	amino	acids,	with	two	catalytic	domains	including	a	GTPase	and	kinase	domain	(Cookson	et	al.,	2010,	Boon	
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et	al.,	2014,	Tsika	et	al.,	2012).	The	GTPase	domain	includes	the	Roc	and	COR	domains,	while	the	kinase	domain	includes	the	MAPKKK	domain	(Figure	1.1).	The	endogenous	mechanisms	of	LRRK2	are	still	being	elucidated,	but	it	is	thought	to	play	an	important	roll	as	a	regulatory	scaffold	for	protein	complexes	(Tsika	et	al.,	2012).	Surprisingly,	LRRK2	is	most	highly	expressed	in	the	liver,	kidneys	and	lymph	nodes,	with	relatively	low	expression	in	the	substantia	nigra	(Tsika	et	al.,	2012).	However,	there	are	somewhat	higher	levels	in	the	striatum	and	other	dopamine	innervated	brain	regions	(Plowey	et	al.,	2011).	Ubiquitous	within	the	cytoplasm,	LRRK2	specifically	localizes	to	organelle	membranes	in	its	dimeric	form	(Tsika	et	al.,	2012,	Gloeckner	et	al.,	2005).		There	are	six	LRRK2	missense	mutations	associated	with	PD	including	the	G2019S,	R1441C,	R1441G,	R1441GH	Y1699C,	and	I2020T	mutations	(Paisán-Ruıź	et	al.,	2004,	Zimprich	et	al.,	2004,	Tsika	et	al.,	2012).	These	fall	into	two	categories.	The	R1441C,	R1441G,	R1441H	and	Y1699C	mutations	are	purported	to	decrease	the	GTPase	activity	of	LRRK2,	while	the	G2019S	and	I2020T	mutations	increase	the	kinase	activity	(Tsika	et	al.,	2012,	Plowey	et	al.,	2011,	Gloeckner	et	al.,	2005).	The	R1441C	and	G2019S	mutations	are	the	most	studied	of	these	five	mutations.	The	R1441C	mutation	reduces	the	GTPase	activity	of	LRRK2	(Cookson	et	al.,	2010,	Tsika	et	al.,	2012,	Nuytemans	et	al.,	2008).	This	could	potentially	cause	increased	binding	of	LRRK2	with	an	unknown	GTP-dependent	interacting	partner	or	prolonged	LRRK2	activity	(Tsika	et	al.,	2012).	The	G2019S	mutation	is	the	most	prevalent	mutation	in	PD.	Up	to	40%	of	familial	cases	have	this	mutation,	and	the	penetrance	increases	
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with	age,	reaching	around	74%	at	79	years	of	age	(Tsika	et	al.,	2012).	1-2%	of	sporadic	cases	have	this	mutation	(Tong	et	al.,	2010).	These	mutations	markedly	alter	the	autoregulation	of	LRRK2.	GTP	binding	is	known	to	alter	the	kinase	activity	of	LRRK2,	and	has	been	deemed	essential	(Xiong	et	al.,	2010,	Taymans	et	al.,	2011,	Ito	et	al.,	2007,	Deng	et	al.,	2008).	GTPase	activity	is	conversely	thought	to	be	regulated	by	autophosphorylation	in	its	dimeric	form	implying	a	reciprocal	regulation	of	LRRK2	by	its	two	active	sites	(Tsika	et	al.,	2012,	Webber	et	al.,	2011).		LRRK2’s	two	catalytic	domains	lend	a	high	level	of	regulation	and	self-regulation	to	the	protein.	While	more	needs	to	be	learned	about	this	regulation,	researchers	have	begun	to	distinguish	the	rolls	and	activity	of	these	domains.		To	further	determine	its	effect	in	PD,	the	physiologic	roll	of	LRRK2	must	be	better	understood	on	the	cellular	level.			 	
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Figure	1.1.	Major	domains	of	LRRK2.	ANK	=	ankyrin-like,	LRR	=	leucine-rich	repeat,	ROC	=	Ras	of	complex,	COR	=	C-terminal	of	ROC.	Mutations	in	red	are	pathogenic.	Mutations	in	orange	are	possible	risk	factors.	Mutations	in	blue	have	been	observed	in	PD	patients	but	are	not	correlated	with	disease.	Mutations	in	the	ROC-COR	domain	effect	the	GTPase	activity,	while	mutations	in	the	kinase	domain	effect	the	kinase	activity	of	LRRK2	(figure	from	Giasson	et	al.,	2008).		 	
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Autophagy	Autophagy	is	a	cellular	mechanism	of	homeostasis.	It	is	the	process	by	which	cells	breakdown	misfolded	proteins,	protein	aggregates	and	dysfunctional	organelles.	Deregulated	in	PD,	it	is	integral	in	regulating	the	life	span	of	proteins,	and	degradation	of	long-lived	proteins	and	organelles.	It	has	also	been	proposed	to	be	an	important	part	of	synaptic	function	and	plasticity	(Plowey	et	al.,	2011,	Cheung	et	al.,	2009).	In	PD,	autophagic	markers	such	as	LC3	are	upregulated	in	substantia	nigra	of	human	brains	(Alvarez-Eriviti	et	al.,	2010)	There	are	three	main	types	of	autophagy:	macroautophagy,	microautophagy	and	chaperone-mediated	autophagy.	While	chaperone-mediated	autophagy	and	the	ubiquitin-proteasome	system	have	been	implicated	in	PD,	macroautophagy	has	been	the	primary	focus	of	numerous	groups	with	the	largest	changes	seen	in	this	area.	When	biologists	talk	about	autophagy	they	are	generally	speaking	about	macroautophagy.	For	the	purposes	of	this	paper,	the	same	will	be	done	(Figure	1.2).	Autophagy	begins	by	the	initiation	of	class	III	phosphoinositide	3-kinase	and	the	formation	of	a	single	membrane	phagophore	(Vergne	et	al.,	2009).	Autophagy-related	gene	6	(Atg6),	also	known	as	beclin-1,	is	similarly	important	for	initiation.	The	Atg-5-Atg12	complex	noncovalently	binds	with	Atg16	and	is	recruited	to	the	phagophore	membrane	(Vergne	et	al.,	2009).		Interestingly,	Atg5	can	function	as	a	proapoptotic	protein	targeted	to	mitochondria	(Codogno	et	al.,	2006).	Also	recruited	to	the	complex	is	light-chain	3	I	(LC3-1),	which	upon	initiation	is	lipidated	into	LC3-II.	This	single	membrane	recruits	misfolded	proteins,	organelles,	etc.	and	raps	
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around	on	itself	forming	a	double	membrane	organelle,	the	autophagosome.	This	is	the	completion	of	the	initiation	phase.	The	autophagosome	then	moves	to	the	lysosome	where	it	fuses	with	the	acidic	lysosome.	After	fusion,	the	newly	formed	autolysosome	can	begin	degrading	the	unwanted	material	into	amino	acids	for	reuse	in	the	cell.			 	
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Figure	1.2.	Model	of	the	three	main	types	of	autophagy:	macroautophagy,		chaperone-mediated	autophagy	(CMA)	and	microautophagy.	Macroautophagy,	herein	referred	to	as	autophagy	is	initiated	by	formation	of	a	phagophore	and	recruitment	of	atg	proteins	and	material	for	degradation.	The	phagophore	is	formed	into	a	double	membrane	autophagosome.	It	can	then	fuse	with	the	lysosome	for	degradation.	We	hypothesize	that	the	fusion	of	the	autophagosomes	to	the	lysosome	is	regulated	by	a	LRRK2-HDAC6	complex.	In	CMA,	proteins	with	a	KFERQ-consensus	motif	are	translocated	directly	across	the	lysosome	membrane	via	binding	to	LAMP-2A.	Microautophagy	occurs	without	protein	unfolding,	where	proteins	may	cross	directly	into	the	lysosome	for	degradation	(adapted	from	Lynch-Day	et	al.,	2012).		 	
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	 Recent	findings	have	begun	to	divulge	the	relationship	between	LRRK2	and	autophagy	(Plowey	et	al.,	2008,	Gomez-Suaga	et	al.,	2012,	Bravo-San	Pedro	et	al.,	2014).	It	is	this	intersection	that	is	one	of	the	most	exciting	and	promising	directions	in	the	field.	Autophagy	could	be	the	link	by	which	dysregulation	occurs	in	PD,	and	LRRK2	the	means	to	regulate	it.	αsyn	inclusions	point	to	an	obvious	error	in	the	autophagic	system,	as	does	the	amassment	of	dysfunctional	mitochondria.	PD	shows	a	clear	dysfunction	in	autophagy	that	better	regulated,	could	be	a	means	to	alleviate	the	degeneration	of	this	debilitating	disease.			
LRRK2	models	and	autophagy	LRRK2	is	a	multifaceted	protein	with	roles	in	vesicular	trafficking	to	translational	control,	but	its	tuned	role	in	autophagy	presents	a	promising	target	in	regulating	dysfunction	of	the	autophagolysosomal	system	in	PD.	Discovered	as	a	PD	linked	gene	in	2004,	the	optimization	of	studying	LRRK2	and	its	effects	on	autophagy	are	still	being	modified.	Dr.	Chu	and	her	group	were	the	first	to	look	at	the	effects	of	the	G2019S	mutation	on	SH-SY5Y	cells	(Plowey	et	al.,	2008).	They	transfected	in	G2019S,	a	kinase	dead	(KD)	mutation,	or	WT	LRRK2	into	cells,	and	saw	neuritic	shortening	with	the	G2019S	mutation	versus	the	KD	and	WT.	Upon	inspection	of	autophagic	vesicles,	the	group	noticed	an	increase,	not	only	in	size,	but	in	numbers	of	these	G2019S	autophagic	vesicles	when	compared	to	the	KD	and	WT.	Interestingly,	they	also	saw	an	increase	in	size	and	quantity	in	the	WT	when	
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compared	to	the	KD.	This	is	a	critical	finding	because	it	shows	where	the	G2019S	mutation	may	fit	into	the	varying	levels	of	LRRK2	activation.	If	KD	is	completely	inactive,	and	the	WT	is	a	baseline	level	of	activation,	it	seems	likely	that	the	G2019S	is	an	overactive	variation.	To	try	and	deduce	the	mechanism	by	which	this	occurs,	they	reversed	the	G2019S-induced	neuritic	shortening	through	RNAi	knockdown	of	Atg7	or	LC3.	They	also	added	the	potent	autophagy	inducer,	rapamycin	to	the	SY5Y	cells	to	see	how	this	affected	the	neuritic	shortening.	While	it	had	no	affect	on	the	WT	or	KD	transfected	cells,	it	increased	the	amount	of	autophagic	vesicles	in	the	G2019S	cells,	as	well	as	further	reducing	neurite	length.	This	lends	further	proof	to	the	hypothesis	that	LRRK2	plays	a	regulatory	roll	in	autophagy,	and	autophagy	influences	neurodegeneration.	Lastly,	the	MAPK/ERK	kinase	(MEK)	inhibitor	U0126	was	used	to	determine	potential	interactors.	They	found	that	inhibitors	of	U0126	assuage	vesicular	accumulation	as	well	as	neuritic	shortening.	The	consequences	of	varying	degrees	of	LRRK2	kinase	and	GTPase	activity	are	slowly	being	elucidated.	One	group	examined	an	overexpression	model	in	HEK293T	cells,	transfecting	in	WT,	KD	and	G2019S	mutants,	and	measured	levels	of	autophagy	with	LC3	as	a	readout	(Gomez-Suaga	et	al.,	2011).	They	found	that	both	the	WT	and	G2019S	mutants	displayed	similar	levels	of	LC3	(Gomez-Suaga	et	al.,	2011).	If	both	WT	and	G2019S	transfected	cells	are	showing	similar	levels	of	autophagy	(possibly	hitting	a	saturation	peak	since	rapamycin	had	no	effect	on	LC3	levels	for	the	WT	and	G2019S),	while	the	KD	is	showing	baseline	levels,	the	kinase	domain	must	be	important	for	the	increase	in	LC3.	The	group	also	examined	the	
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Ca2+/CaMKK/AMPK	pathway,	finding	that	overexpression	of	WT	and	G2019S	significantly	increased	AMPK	activity.	Treatment	with	an	AMPK	inhibitor	attenuated	the	increase	in	autophagosomes,	while	using	the	calcium	chelator,	BAPTA-AM	also	blocked	this	increase.	No	decrease	was	seen	with	the	chelator	when	autophagy	was	induced	with	rapamycin,	suggesting	a	specific	interaction	with	LRRK2.T	An	increase	in	LRRK2	activity	leads	to	changes	in	autophagy.	Other	manipulations	that	block	autophagy,	Spautin-1,	for	example,	is	a	potent	inhibitor	of	autophagy,	known	to	knock	down	Beclin1	(Liu	et	al.,	2011),	or	phosphorylation	of	LC3	have	been	shown	to	prevent	LRRK2-mediated	neurite	retraction	in	primary	neuronal	cultures	(Plowey	et	al.,	2011).		Tied	to	αsyn	inclusions	and	dysfunctional	mitochondria	accumulations,	autophagy	may	be	the	unifying	mechanism	that	causes	the	pathology	of	PD.	Mice	with	neuronal	autophagy-gene	knockouts	develop	intraneuronal	aggregates	and	neurodegeneration	(Rubinsztein	et	al.,	2006).	Conversely,	studies	have	shown	that	excessive	activation	of	autophagy	has	been	equally	detrimental	and	caused	cell	death	(Cheung	et	al.,	2009).	This	suggests	that	basal	levels	of	autophagy	are	necessary	for	the	clearance	of	protein	aggregates,	and	that	these	inclusions	may	even	be	protective	in	the	disease	(Cheung	et	al.,	2009).	Also,	neuritic	autophagy	has	been	shown	to	be	responsible	for	neurite	retraction	since	inhibition	of	autophagy	via	LC3	or	Atg7	knockdown	reversed	this	phenotype	(Plowey	et	al.,	2008).	Generation	of	transgenic	mouse	models	has	been	an	indispensable	tool	in	the	study	of	LRRK2,	particularly	a	LRRK2	mouse	model	of	PD	with	human	WT,	G2019S	
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and	R1441C	LRRK2	(Ramonet	et	al.,	2011).	These	mice	exhibit	many	of	the	hallmark	signs	of	PD	including	ubiquitous	and	high	levels	of	expression	of	LRRK2,	an	18%	reduction	of	dopamine	neurons	in	the	SNpc,	and	appropriately,	no	reduction	in	the	ventral	tegmental	area.	When	neuronal	cultures	were	taken	from	these	mice,	the	G2019S	mutants	showed	a	significant	reduction	in	neuritic	complexity	at	days	in-vitro	(DIV)	7,	in	line	with	studies	of	neurite	shortening	by	the	G2019S	mutation	(Plowey	et	al.,	2008).	These	mice	similarly	display	enlarged	early	and	late	stage	autophagosomes	throughout	the	soma	and	axons,	as	well	as	condensed	mitochondria.	However	αsyn	inclusions	were	notably	absent.		Another	group	produced	a	LRRK2	-/-	mouse	with	the	purpose	of	elucidating	the	physiological	mechanism	of	LRRK2	(Tong	et	al.,	2010).	However,	these	mice	showed	no	neuronal	degeneration.	There	was	no	difference	in	levels	of	dopamine	or	tyrosine	hydroxylase	positive	neurons	between	knock	out	(KO)	and	WT	mice.	In	addition,	there	was	no	accumulation	of	αsyn	in	KO	mice	at	2	years	of	age.	What	the	group	did	find	was	age-dependent	renal	atrophy.	The	kidneys	in	the	KO	mice	at	20	months	of	age	were	noticeably	smaller	and	weighed	31%	less	then	the	WT	mice.	The	group	observed	a	dramatic	accumulation	of	αsyn	in	the	kidneys	of	the	KO	mice,	whereas	there	was	very	little	in	the	WT	mice.	This	is	not	surprising	since	LRRK2	exhibits	higher	expression	levels	in	the	kidneys	along	with	the	liver	and	lymph	nodes.	Measuring	the	occurrence	of	autophagy	in	the	kidneys,	they	saw,	not	only	an	increase	in	lipofuscin	granules	(undigested	lysosomal	material)	at	20	months	of	age,	but	they	also	showed	a	decrease	in	the	amount	of	LC3-II	and	an	increase	in	LC3-I.	
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Knowing	that	inhibition	of	autophagy	by	inactivation	of	Atg7	leads	to	an	upregulation	in	p62	(another	marker	for	autophagy),	they	also	examined	p62	levels	and	saw	an	increase	in	the	KO	mice.	This	indicated	a	decrease	in	autophagosome	formation,	revealing	that	the	absence	of	LRRK2	reduces	autophagic	activity.	This	group	came	out	with	another	study	looking	at	bi-phasic	alterations	in	autophagy	(Tong	et	al.,	2012).	They	looked	at	autophagic	activity	at	three	different	time	points:	1	month	of	age,	7	months	and	20	months.	They	found	a	surprising	difference	between	the	three	time	points	by	looking	at	changes	in	the	levels	of	LC3-I/II.	At	1	month	of	age,	the	KO	mice	showed	no	difference	in	autophagy	when	compared	to	the	WT	mice.	At	7	months	of	age	they	showed	enhanced	autophagy.	And	at	20	months	they	showed	a	decrease	in	autophagy.	Their	study	suggests	that	LRRK2	is	not	necessary	for	autophagy	since	it	is	highly	upregulated	at	7	months	of	age	in	the	KO	mice,	but	that	it	is	an	important	part	of	its	regulation.	These	show	biphasic	alterations	in	autophagy	and	a	general	loss	in	autophagic	markers	suggesting	an	overall	decrease	in	autophagy	in	the	absence	of	LRRK2.	The	answers	are	still	unclear,	and	the	roll	of	autophagy	in	PD	is	in	need	of	illumination.	What	is	apparent	is	that	any	large	increase	or	decrease	in	autophagy	can	be	harmful.			
Histone	deacetylase	6	HDAC6	is	a	microtubule-associated	deacetylase	that	plays	a	role	in	regulating	microtubule	acetylation	and	cell	motility	via	Hsp90	and	Rac1	binding	(Zang	et	al.,	2007,	Boyault	et	al.,	2007).	There	are	three	major	classes	of	HDACs,	with	HDAC6	and	
		
27 
HDAC10,	the	only	two	HDACs	in	Class	IIa	(Dokmanovic	et	al.,	2007).	They	are	also	the	only	two	HDACs	located	mainly	in	the	cytoplasm.	Most	classes	of	HDACs	are	inhibited	by	trichostatin	A	(TSA).	Tubacin	is	able	to	selectively	inhibit	HDAC6	leading	to	increases	in	acetylated	tubulin	(Dokmanovic	et	al.,	2007).	HDAC6	has	two	catalytically	active	deacetylase	domains	and	an	ubiquitin	binding	zinc	finger	(Zhang	et	al.,	2007).	Upon	proteasome	inhibition,	the	zinc	finger	binds	ubiquitin,	and	associates	with	aggresomes	(Boyault	et	al.,	2007).	In	2003	a	group	demonstrated	that	HDAC6	is	the	bridge	between	dynein	and	polyubiquitinated	proteins,	transporting	misfolded	proteins	in	the	cell	(Kawaguchi	et	al.,	2003).	Recent	studies	have	also	linked	HDAC6	to	autophagy.	One	group	discovered	the	necessity	of	HDAC6	for	autophagic	compensation	during	UPS	impairment	(Pandey	et	al.,	2007).	While	another	group	demonstrated	the	importance	of	HDAC6	for	the	fusion	of	the	autophagosome	and	lysosome	specifically	in	quality	control	autophagy	via	an	f-actin	network	(Lee	et	al.,	2010).	HDAC6	interfaces	with	autophagy	and	quality	control	at	multiple	points,	regulating	microtubule-based	delivery	of	material	to	the	autophagosome	as	well	as	fusion	of	the	autophagosome	with	the	lysosome	to	form	the	autolysosome	(Lee	et	al.,	2010).		
Stress	granules	Stress	granule	(SG)	formation	has	emerged	in	the	field	of	neurodegeneration	as	a	compelling	mechanism	tightly	correlated	with	diseased	states.		The	translational	response	to	stress	is	mediated	in	part	by	aggregation	of	RNA	binding	
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proteins	(RBPs)	to	form	SGs.	The	proteins,	T-cell	intracellular	antigen	1	(TIA-1),	TTP,	RasGAP-associated	endoribonuclease	(G3BP),	eIF2α,	HuR	(ELAVL1)	and	HuD	(ELAVL4)	are	some	of	the	RBPs	integral	to	the	SG	process.	Upon	cellular	stress,	which	comprises	any	stress	ranging	from	heat	shock	to	reactive	oxygen	species	to	misfolded	and	aggregated	proteins,	eIF2α	is	phosphorylated	and	protein	translation	switches	from	cap-dependent	to	cap-independent	translation	(Kedersha	et	al.,	2007).	mRNA	that	is	not	necessary	for	survival	is	sequestered	into	SGs	by	TIA-1,	TTP	and	other	nucleating	RBPs.	Upon	removal	of	the	stress,	SGs	may	disassemble	and	mRNA	unbound	for	translation,	or	SGs	and	their	contents	may	be	targeted	for	degradation	to	processing	bodies	(Decker	et	al.,	2012).	During	stress,	housekeeping	proteins	necessary	for	cellular	homeostasis	and	stress	abrogation	continue	synthesis.	However,	like	any	cellular	process,	over	activity	can	be	detrimental	to	the	cell,	and	it	is	important	to	understand	at	what	level	the	SG	pathway	is	activated	in	diseased	brains.	SG	formation	has	recently	been	tied	to	a	number	of	degenerative	disorders	including	AD	and	amyotrophic	lateral	sclerosis	(ALS)	(Vanderweyde	et	al.,	2012,	Liu-Yesucevitz	et	al.,	2010).	Previous	work	from	our	lab	in	AD	brains	demonstrates	co-localization	of	tau	pathology	with	the	RBP	TIA-1,	highlighting	a	significant	increase	in	SGs	in	aged	AD	brains	(Vanderweyde	et	al.,	2012).		Other	studies	have	begun	to	find	regulatory	relationships	between	autophagy	and	SGs.	One	group	found	that	knockdown	(KD)	of	ATG5	impaired	the	formation	of	SGs	(Seguin	et	al.,	2014).	While	another	group	found	that	HuD	plays	an	important	roll	in	the	expression	of	autophagy	related	proteins,	specifically	atg5	
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(Kim	et	al.,	2013).	HuD	stabilizes	mRNA	transcripts	by	binding	them	and	preventing	their	degradation	by	processing	bodies.	This	group	found	that	HuD	stabilizes	ATG5	mRNA.	KD	of	HuD	lead	to	a	reduction	in	the	atg5,	while	overexpressing	it	lead	to	its	increase	(Kim	et	al.,	2013).	This	is	exciting	work	not	only	because	it	ties	an	RBP,	HuD	to	autophagy,	a	processes	highly	deregulated	in	PD,	but	because	it	specifically	relates	HUD,	a	gene	associated	with	age	at	onset	in	PD	(Noureddine	et	al.,	2005)			
Hypothesis	and	specific	aims	There	are	numerous	pathways	that	are	perturbed	in	PD,	but	many	of	them	arguably	stem	from,	or	are	correlated	with	autophagic	processes.	The	tight	correlation	of	LRRK2	with	autophagic	dysfunction	in	PD,	along	with	the	recent	elucidation	of	a	LRRK2-HDAC6	regulatory	network	led	us	to	our	first	hypothesis;	
HDAC6	and	LRRK2	interact	to	regulate	autophagy.	We	sought	to	answer	this	through	our	first	aim;		Aim	one:	Determine	whether	regulation	of	autophagy	by	LRRK2	requires	
HDAC6.		The	role	of	LRRK2	in	translation,	along	with	recent	determinates	by	our	lab	of	differential	regulation	of	RBPs	in	AD	patients,	further	led	us	to	our	second	hypothesis;	the	pathophysiology	of	PD	leads	to	differential	expression	and/or	
localization	of	key	RBPs	implicated	in	the	SG	response.	We	examined	this	through	our	second	aim	and	third	aim;		
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Aim	two:	determine	whether	the	regulation	of	RBPs	is	altered	in	PD	and	
related	diseases.	Aim	three:	determine	whether	αsyn	or	autophagy	modifies	the	SG	response.		We	hoped	that	through	elucidation	of	these	two	seemingly	separate	pathways,	a	unification	of	multiple	pathways	might	converge	on	autophagy	as	the	novel	cellular	processes	to	target	in	PD.		
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Introduction		 Mutations	in	LRRK2	are	among	the	most	prevalent	genetic	changes	that	are	associated	with	familial	and	sporadic	PD.	Multiple	groups,	including	our	own,	have	shown	that	LRRK2	is	a	potent	regulator	of	autophagy	using	approaches	that	include	gene	knockdown,	gene	overexpression	and	direct	inhibition	of	autophagy	(Saha	et	al.,	2015,	Cookson	et	al.,	2010,	Gan-Or	et	al.,	2015	et	al.,	Orenstein	et	al.,	2013).	These	studies	have	shown	effects	in	vitro,	as	well	as	in	animal	models	(e.g.,	C.	
elegans,	knockout	mice)	and	PD	brains,	making	LRRK2	a	good	candidate	for	studying	autophagy	in	PD.		Previously,	we	used	a	combined	in	silico-in	vivo	approach	to	elucidate	the	gene	regulatory	networks	linked	to	LRRK2	(Applying	systems	biology	algorithms,	shown	to	be	highly	effective	in	prokaryotic	systems,	we	applied	a	systems	biology	algorithm,	termed	Context	Likelihood	of	Relatedness	(CLR),	to	develop	LRRK2	regulatory	networks	based	on	transcriptomes	obtained	from	human	brain,	blood,	as	well	as	from	C.	elegans	(Dusonchet	et	al.,	2014,	Faith	et	al.,	2007).	We	used	the	resulting	regulatory	network	to	guide	reverse	genetic	screens,	examining	the	actions	of	LRRK2	interactors	on	survival	of	dopaminergic	neurons	in	C.	elegans.	The	results	showed	that	genes	regulating	autophagy	exhibited	a	consistently	strong	effect	on	dopaminergic	neuronal	survival	(Dusonchet	et	al.,	2014).	Interestingly,	HDAC6	appeared	as	one	of	the	proteins	with	the	largest	number	of	links	in	the	LRRK2	regulatory	network,	pointing	to	HDAC6	as	a	potential	important	LRRK2	interactor	
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with	extensive	regulation	of	numerous	other	genes	that	exhibited	mutual	regulation	by	both	proteins	(Dusonchet	et	al.,	2014).	Given	the	strong	involvement	of	both	LRRK2	and	HDAC6	with	autophagy,	we	decided	to	investigate	whether	LRRK2	might	regulate	autophagy	through	interaction	with	HDAC6.	Here	we	show	that	HDAC6	exhibits	functional	and	physical	interactions	with	LRRK2.	HDAC6	forms	a	complex	with	LRRK2,	is	phosphorylated	by	LRRK2	and	phosphorylation	of	HDAC6	is	strongly	increased	in	brains	from	patients	with	sporadic	PD.	HDAC6	and	LRRK2	exhibit	additive	increases	in	tubulin	deacetylase	activity.	LRRK2	also	exerted	strong	effects	on	the	autolysosomal	system.	RNAi	experiments	reveal	that	LRRK2	constructs	with	disease-associated	mutations	exhibit	increased	dependence	on	HDAC6	for	regulation	of	autophagy.	Deletion	experiments	using	C.	elegans	show	that	HDAC6	is	also	necessary	for	LRRK2	action	in	vivo.		This	work	identifies	a	critical	role	for	the	HDAC6	in	LRRK2	function,	and	suggests	an	important	role	of	HDAC6	in	the	pathophysiology	of	disease-linked	LRRK2	mutations.	These	results	highlight	a	novel	mechanism	for	regulation	of	mutant	LRRK2	deficits	through	the	pleiotropic	action	of	HDAC6,	and	identify	a	pathway	by	which	mutations	in	LRRK2	could	mediate	PD.	dissertation	goes	here.	
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Methods	
Systems	biology	analysis	and	C.	elegans	RNAi	and	DA	survival	analysis	PD	patient	microarray	data	and	C.	elegans	RNAi	data	were	collected	and	analyzed	as	previously	described	using	the	CLR	algorithm	and	the	Mode	of	Action	by	Network	Identification	algorithm	(Dusonchet	et	al.,	2014).	Nematodes	were	maintained	under	standard	conditions	(Brenner	et	al.,	2014).	The	generation	of	nematodes	expressing	human	LRRK2	neuronally	was	described	in	detail	in	Saha	et	al	as	well	as	a	detailed	description	of	C.	elegans	dopamine	neuronal	survival	assays	(Saha	et	al.,	2009).	
	
Cell	culture	and	transfection	HEK293FT	cells	were	maintained	in	Dulbecco’s	modified	Eagle’s	medium	(DMEM)	(Invitrogen,	Carlsbad,	CA,	USA)	supplemented	with	10%	fetal	bovine	serum	(FBS)	(Atlanta	Biologicals,	Lawrenceville,	GA,	USA),	non-essential	amino	acids,	penicillin	(100	units/mL),	and	streptomycin	(100	μg/mL).	Tetracyline-inducible	HEK293	cells	expressing	V5-tagged	LRRK2	constructs	were	generated	using	the	Flp-In	T-Rex	system	(Invitrogen;	Chan	et	al.,	2011).	FlpIn	T-Rex	HEK293	LRRK2	stable	cell	lines	were	maintained	in	DMEM	supplemented	with	10%	tetracycline-free	FBS	(Atlanta	Biologicals),	non-essential	amino	acids,	penicillin/	streptomycin,	50	μg/ml	hygromycin	(Invitrogen)	and	15	μg/mL	blasticidin	(Invitrogen).	Cells	were	plated	in	12	well	plates	(Nunc)	at	150,000	cells/mL.	SH-SY5Y	human	neuroblastoma	cells	were	maintained	in	DMEM	supplemented	with	10%	FBS,	2mM	L-glutamine,	10	mM	
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HEPES,	and	no	antibiotics.	Cells	were	plated	at	a	density	of	5	x	104/cm2	on	poly-L-lysine-coated	glass	coverslips	with	the	same	media	formulation	supplemented	with	10	μM	retinoic	acid	to	induce	differentiation	for	72	h	prior	to	transfection.	After	72	h,	the	differentiated	SH-SY5Y	cells	were	transfected	with	Lipofectamine	2000	(Invitrogen)	(Plasmids	listed	in	Dusonchet	et	al.,	2014).	For	HDAC6	RNAi	experiments,	SH-SY5Y	cells	were	transfected	using	Lipofectamine	RNAiMAX	(Invitrogen)	with	siGENOME	SMARTpool	HDAC6	(Dharmacon	#M-003499-00-0005)	one	day	prior	to	transfection	as	previously	described	(Zaarur	et	al.,	2014).	These	cells	were	transfected	24	hours	later	with	0.5	μg	of	LC3-RFP-GFP	and	1.1	μg	of	either	empty	vector	plasmid	(pcDNA	3.1+	Invitrogen),	WT	LRRK2,	G2019S	LRRK2	or	R1441C	LRRK2.	Lipofectamine	2000	(Invitrogen)	was	used	at	a	1:2.5	DNA	to	Lipofectamine	ratio.	Cells	were	transfected	for	72	hours	before	fixation.		
	
Co-immunoprecipitation	(Co-IP)	assay	and	western	blot	analysis	Samples	from	3	human	striatal	samples	(Age:	84,	79,79,	PMI:	3,3,	N.A.,	Gender:	M,F,F)	were	homogenized	and	sonicated	in	IP	buffer.		IP	buffer	consisted	of	0.5%	Triton	X-100,	1mM	EDTA	and	HALT	protease	inhibitor	cocktail	(Promega).		The	lysates	were	rotated	at	4	°C	for	30	minutes	followed	by	centrifugation	at	13,000g	for	10	minutes.	The	supernatant	was	pre-cleared	with	rec-Protein	G	Sepharose	4B	Fast	Flow	(Invitrogen)	followed	with	addition	of	the	appropriate	antibody	and	rotated	overnight	at	4	°C.	rec-Protein	G	Sepharose	was	added	to	pull	down	the	antibody	pre-complex.	The	Sepharose	beads	were	stringently	washed	
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three	times	with	IP	buffer.	The	IP	proteins	were	eluted	in	lithium	dodecyl	sulphate	(LDS)	sample	buffer	(Invitrogen)	by	heating	at	95	°C	for	3	minutes.	Immunoprecipitates	were	resolved	by	3–8%	NuPAGE	Tris-Acetate	or	4–20%	Tris-Glycine	gels	(Invitrogen)	and	analyzed	by	western	blot.	Antibodies	were	purchased	from	Millipore	(actin),	Novus	(LRRK2),	and	Santa	Cruz	(RGS2).	HEK293T	lysates	were	run	as	previously	described	(Dusonchet	et	al.,	2014)	on	4-20%	tris	glycine	gels	(Invitrogen),	transferred	overnight	to	PVDF	and	blocked	in	5%	powdered	milk,	5%	gelatin	or	5%	PBS.		After	washing,	the	membranes	were	blotted	for	V5	(V5-10,	cat	#	V8012,	Sigma),	HA	(C29F4,	cat	#	37245,	Cell	Signaling),	HDAC6	(H-300,	cat	#	sc-11420,	Santa	Cruz),	phospho-HDAC6	(phospho-Ser22,	cat	#	A941,	Assay	Biotechnology),	actin	(C4,	cat	#	MAB1501,	Millipore),	p62	(Ab511,	cat	#	5114S,	Cell	Signaling)	and	LC3	(LC3B,	cat	#	2775S,	Cell	Signaling).		
	
Kinetic	analysis	of	LRRK2-catalyzed	HDAC6	phosphorylation	The	kinase	assay	for	phosphorylation	of	His-tagged	HDAC6	was	conducted	in	buffer	containing	20	mM	HEPES	(pH	7.4),	50	mM	NaCl,	10	mM	MgCl2,	1	mM	DTT,	BSA	0.5	mg/ml,	1	mM	beta-Gly-PO4,	0.09	µM	HDAC6	(Enzo),	200	µM	ATP,	and	10	µCi	[γ-33P]-ATP	(PerkinElmer).	The	reactions	were	conducted	in	duplicate,	initiated	by	the	addition	of	various	concentrations	of	GST-tagged	LRRK2	(Invitrogen)	in	the	range	of	0	-	48	nM,	and	incubated	at	room	temperature	for	various	periods	of	time.	The	reaction	was	stopped	by	the	addition	of	20	mM	EDTA.	The	mixture	was	transferred	to	a	nickle-coated	96-well	flash	plate	(PerkinElmer)	and	incubated	for	
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1h	at	RT.	Finally,	the	plate	was	washed	six	times	with	75	mM	H3PO4	and	was	read	by	Trilux	plate	reader	(PerkinElmer).	In	all	cases,	reaction	progress	curves	for	production	of	phospho-HDAC6	were	linear	over	at	least	3h.	
	
LRRK2-catalyzed	HDAC6	phosphorylation	analyzed	by	autoradiography	The	kinase	assay	for	phosphorylation	of	GST-tagged	HDAC6	was	conducted	in	the	buffer	mentioned	above	at	1	µg	HDAC6	(Abnova),	200	µM	ATP,	and	20	µCi	[γ-
33P]-ATP	(PerkinElmer).	The	reactions	were	initiated	by	the	addition	of	12	nM	LRRK2	(Invitrogen)	and	incubated	at	room	temperature	over	night.	Background	reaction	was	conducted	in	the	absence	of	LRRK2.	The	reaction	was	stopped	by	the	addition	of	2X	SDS	sample	buffer	and	the	mixture	was	boiled	for	5	min.		
	
Postmortem	human	tissue	samples	Flash	frozen	human	caudate	tissue	samples	were	provided	by	the	Queen	Square	Brain	Bank	(QSBB)	at	the	UCL	Institute	of	Neurology	(London,	UK),	where	donated	brains	are	collected	using	ethically	approved	protocols	under	a	human	tissue	authority	license	(No.	12198).	The	average	ages	and	post-mortem	intervals	for	each	set	of	samples	were:		Control	83.0	±	7.0	yrs,	44.6	±	13.3	hrs,	N=9;	PD	74.3	±	6.0	yrs,	43.7	±	16.8	hrs,	N=9;	G2019S	LRRK2,	81.7	±	2.1	yrs,	30.5	±	14.8	hrs,	N=3.	Samples	were	homogenized	as	previously	described	(Dusonchet	et	al.,	2014).		
	
Quantitative	image	analysis	
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After	48	h,	transfected	cells	were	fixed	with	4%	paraformaldehyde	in	PBS	for	13	min	at	room	temperature,	followed	by	3	x	5	min	washes	in	PBS.	Coverslips	were	then	mounted	in	Prolong	Gold	Antifade	mounting	medium	(Invitrogen).	Random	fields	of	GFP-transfected	cells	at	40x	magnification	were	photographed	(Olympus	BX60)	by	an	individual	blinded	to	the	experimental	conditions.	Images	were	analyzed	using	an	ImageJ	macro	that	defined	the	cell	and	quantified	the	size	of	the	largest	autophagosome.	N=50	cells	quantified	per	condition.		
	
Statistical	analysis	Analysis	was	completed	using	the	GraphPad	Prism	program,	and	varied	depending	on	the	particular	study.	They	included	one-way	ANOVA	with	Tukey’s	post	hoc	testing	and	student’s	T-test.	Error	bars	reflect	SEM	values.				
Results	
HDAC6	is	genetically	link	to	LRRK2	and	autophagy	We	previously	described	a	large-scale	systems	biology	analysis	of	human	brain	and	white	blood	cells	that	identified	600	human	transcripts	exhibiting	regulatory	association	with	the	LRRK2	transcript	(Dusonchet	et	al.,	2014).	Functional	interactions	between	LRRK2	and	the	transcriptional	regulatory	neighbors	of	LRRK2	were	evaluated	by	knocking	down	each	gene	using	a	C.	elegans	line	expressing	human	LRRK2	(Saha	et	al.,	2009,	Dusonchet	et	al.,	2014).		This	
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approach	identified	200	human	genes,	corresponding	to	181	nematode	homologues,	which	modified	LRRK2	function	in	vivo	(Dusonchet	et	al.,	2014).	To	gain	an	overview	of	the	roles	of	LRRK2	in	common	cellular	processes,	we	grouped	the	genes	in	the	LRRK2	regulatory	network	based	on	function	gene	ontology	(GO)	annotations,	using	effects	on	survival	of	DA	neurons	in	C.	elegans	after	rotenone	treatment	from	our	original	publication	as	a	readout	(Fig.	1A)	(Dusonchet	et	al.,	2014).	The	“Autophagy/Endosomal/Lysosomal”	group	had	the	largest	absolute	effect	size	with	64%	(Fig.	1A),	indicating	that	protection	by	WT	LRRK2	is	strongly	linked	to	normal	autophagic	function	in	C.	elegans.		The	gene	HDAC6	stood	out	as	a	particularly	strong	modifier	of	LRRK2	function	suggesting	that	it	is	an	important	regulatory	neighbor	for	LRRK2	(Dusonchet	et	al.,	2014).	Because	recent	studies	suggest	that	LRRK2	also	modifies	acetylation,	we	were	curious	to	explore	interactions	between	LRRK2	and	HDAC6	proteins	(Godena	et	al.,	2014,	Law	et	al.,	2014).	A	strength	of	the	regulatory	PD	network	developed	by	our	team	is	that	it	can	be	used	to	determine	the	regulatory	network	interactions	in	PD	for	any	gene	by	selecting	the	query	gene	as	a	“seed”;	the	network	algorithm	then	identifies	all	primary,	secondary	and	tertiary	transcriptional	regulatory	neighbors	(Dusonchet	et	al.,	2014).	Using	this	approach,	we	proceeded	to	seed	a	network	with	HDAC6.	The	resulting	list	of	primary	regulatory	neighbors	is	shown	in	Figure	2.1B.	We	then	cross-referenced	these	genes	with	the	primary	and	secondary	network	neighbors	of	
LRRK2.	The	output	demonstrated	a	surprisingly	strong	link	between	LRRK2	and	
HDAC6,	with	41	out	of	43	(95.3%)	HDAC6	primary	neighbors	present	as	primary	or	
		
40 
secondary	neighbors	in	the	LRRK2	regulatory	network	(Fig.	2.1	B).	The	large	number	of	transcripts	sharing	regulation	by	LRRK2	and	HDAC6	suggested	that	HDAC6	might	interact	with	LRRK2	at	both	the	functional	and	physical	level.			 	
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Figure	2.1.	Functional	characterization	of	screen	hits	and	HDAC6	first	neighbor	regulatory	interactors.	(A)	Wormbase	and	GO	Ontology	generated	functional	characterization	of	the	screen	hits	(Dusonchet	et	al.,	2014).	(B)	HDAC6	first	neighbor	regulatory	interactors	derived	using	the	CLR	algorithm	and	the	PD-based	transcriptome	data	(Faith	et	al,	2007,	Dusonchet	et	al.,	2014).	Actin	is	highlighted	in	yellow	as	the	only	gene	that	is	a	first	neighbor	of	HDAC6	and	LRRK2.		Blue	circles	identify	other	genes	present	in	the	LRRK2	sub-network;	green	circles	are	not	present	in	the	LRRK2	sub-network.	(Figure	generated	by	Hu	Li.)				 	
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LRRK2	binds	HDAC6		 To	test	whether	LRRK2	and	HDAC6	interact	as	part	of	a	complex,	we	IPed	LRRK2	and	HDAC6	from	human	brain.	LRRK2	was	IPed	from	human	striatal	tissue,	and	the	resulting	IPs	probed	for	HDAC6	(Fig.	2.2	A).	HDAC6	was	readily	detectable	in	the	striatal	lysates	(control	1,	control	2)	but	absent	from	solutions	containing	only	IgG,	demonstrating	the	specificity	of	the	IP,	and	the	ability	to	detect	interactions	with	endogenous	proteins.	These	data	suggest	that	endogenous	HDAC6	and	LRRK2	interact	as	binding	partners	in	vivo	(Fig.	2.2	A).	To	test	PD-associated	mutations	in	LRRK2	modify	binding	to	HDAC6,	HEK	293	cells	were	co-transfected	with	LRRK2	(WT,	G2019S	and	R1441C,	each	tagged	with	V5)	and	HDAC6	(tagged	with	FLAG),	and	the	V5-LRRK2	IPed.		Each	LRRK2	construct	readily	co-IP	with	HDAC6,	with	no	consistent	mutation	dependent	differences	(Fig.	2.2	B).		Some	non-specific	binding	to	the	anti-V5-sepharose	beads	was	noted	in	HDAC6	over-expressing	cells	(Fig.	2.2	B,	lane	2),	but	significantly	more	HDAC6	was	immunoprecipitated	upon	over-expressing	V5-LRRK2.	These	studies	indicate	that	LRRK2	binds	HDAC6	both	in	vivo	and	in	vitro.			 	
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Figure	2.2.	Association	of	LRRK2	with	HDAC6.	(A)	Co-IP	of	LRRK2	from	human	striatal	tissue	identified	HDAC6	as	a	LRRK2	binding	partners	in	vivo.	(B)	Co-IPs	from	HEK	293T	cells	transfected	with	V5-LRRK2	and	FLAG-HDAC6	show	HDAC6	binding	mutant	LRRK2	as	well	as	WT	LRRK2.		(Immunoblot	produced	by	Joon	Boon.)		 	
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LRRK2	phosphorylates	HDAC6		 The	strong	binding	of	LRRK2	to	HDAC6	led	us	to	examine	whether	LRRK2	phosphorylates	HDAC6.	To	test	for	phosphorylation,	recombinant	LRRK2	was	incubated	for	3	hrs	with	recombinant	HDAC6	in	reaction	buffer	containing	32P-ATP.		The	products	were	then	separated	by	gel	electrophoresis	and	autoradiographed.	A	prominent	band	at	150	KD	(consistent	with	the	size	of	HDAC6)	was	greatly	increased	in	the	HDAC6/LRRK2	vs.	HDAC6	reaction	mixtures,	while	autophosphorylation	of	the	recombinant	LRRK2	(205	KD)	was	minimal	(Fig.	2.3	A).	Next	we	examined	the	kinetics	and	dose	dependence	of	the	reaction.	Phosphorylation	of	recombinant	HDAC6	by	recombinant	LRRK2	was	monitored	by	quantitative	scintillation	fluorescence	using	nickel	capture	adsorption	to	capture	and	wash	the	recombinant	(His)6-HDAC6	(Fig	2.3	B).	Co-incubating	HDAC6	with	WT	LRRK2	in	reaction	buffer	produced	a	dose	and	time-dependent	increase	in	HDAC6	phosphorylation,	as	shown	by	measuring33P	radioactivity	of	HDAC6	by	scintillation	fluorescence	(Fig.	2.3	B);	importantly	little	reactivity	was	evident	upon	omission	of	HDAC6	(data	not	shown).	To	determine	whether	phosphorylation	of	HDAC6	might	be	relevant	to	the	pathophysiology	of	PD,	we	examined	levels	of	phospho-HDAC6	in	striatal	tissue	from	subjects	with	sporadic	PD	and	neurologic	controls.		Levels	of	phospho-HDAC6	were	significantly	elevated	in	subjects	with	sporadic	PD	(Fig.	2.3	C-D),	suggesting	the	involvement	of	HDAC6	phosphorylation	in	the	pathophysiology	of	PD.				 	
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Figure	2.3.	LRRK2	phosphorylates	HDAC6.	(A)	LRRK2	phosphorylates	HDAC6	in	a	manner	that	is	dose	and	time	dependent.	Recombinant	truncated	LRRK2	at	12	nM	was	incubated	with	80	nM	recombinant	HDAC6	in	buffer	containing	200	µM	ATP	(10	µCi	33P-gATP)	for	varying	periods	of	time	(left	panel)	or	for	3	hrs	at	varying	doses	(right	panel)	at	which	point	HDAC6	was	separated	from	LRRK2	by	absorption,	then	washed	and	quantified.	(B)	LRRK2	phosphorylates	HDAC6.		Samples	were	incubated	with	12	nM	LRRK2	for	3	hrs	in	buffer	containing	200	µM	ATP	(10	µCi	33P-gATP),	separated	by	SDS	gel	electrophoresis	and	exposed	for	autoradiography.	(C-D)	Immunoblot	of	phospho-HDAC6	shows	that	phosphorylation	of	HDAC6	is	increased	in	caudate	lysates	(1%	triton	X-100	soluble)	from	PD	(sporadic)	compared	to	neurologically	normal	subjects.		(Work	done	by	Min	Liu	and	Julien	Dusonchet.)		 	
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LRRK2	reduces	tubulin	acetylation	in	an	HDAC6-dependent	manner	The	ability	of	LRRK2	to	phosphorylate	HDAC6	raised	the	possibility	that	LRRK2	binds	and	regulates	HDAC6	activity.	α-Tubulin	is	one	of	the	major	targets	of	HDAC6,	and	readily	examined	because	antibodies	have	been	developed	that	recognize	the	acetylation	site.		In	addition,	previous	studies	indicate	that	LRRK2	reduces	tubulin	acetylation,	and	that	LRRK2	knockout	increases	tubulin	acetylation	(14).	We	proceeded	to	test	whether	the	action	of	LRRK2	on	tubulin	acetylation	is	modulated	by	HDAC6.	WT	LRRK2	was	co-transfected	with	HDAC6,	and	tubulin	acetylation	was	measured	by	immunoblot.		Over-expressing	HDAC6	or	LRRK2,	reduced	tubulin	acetylation	(Fig.	2.4	A).		Over-expressing	HDAC6	with	LRRK2	produced	an	additive	effect,	strongly	decreasing	total	tubulin	acetylation	(Fig.	2.4	A).	LRRK2	constructs	carrying	disease-linked	mutations	in	LRRK2	(G2019S,	R1441C,	Y1699C	and	I2020T)	retained	the	ability	to	increase	HDAC6–mediated	tubulin	deacetylation,	and	showed	a	trend	towards	enhanced	deacetylation	when	compared	with	WT	LRRK2	(Fig.	2.4	B).	These	data	suggest	that	LRRK2	interacts	with	HDAC6,	and	stimulates	HDAC6-mediated	deacetylation.	We	also	attempted	to	examine	tubulin	acetylation	in	postmortem	control	and	PD	brain	lysates,	however	this	post-translational	modification	is	labile	post-mortem	so	no	group	differences	were	evident	(data	not	shown).	
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Figure	2.4.	LRRK2	potentiates	HDAC6	deacetylase	activity.	(A)	WT	LRRK2	stably	expressed	in	HEK	293	cells,	under	control	of	a	tetracycline-inducible	promoter,	was	induced,	and	then	after	24	hrs	the	cells	were	treated	with	bafilomycin	(200	nM)	for	3	hrs.	The	cells	were	then	lysed	and	immunoblotted.	(B)	Disease-linked	LRRK2	mutations	also	increase	HDAC6	mediated	deacetylation.	HEK293	cells	were	transfected	with	LRRK2	(WT,	G2019S,	R1441C,	Y1699C,	I2020T)	±	HDAC6.	After	24	hrs	tubulin	acetylation	was	analyzed	by	immunoblot.	(Immunoblot	run	by	Allison	Citro.)	
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HDAC6	modulates	LRRK2-mediated	autophagy	An	increasing	number	of	reports	indicate	that	LRRK2	can	regulate	autophagy	(Lee	et	al.,	2010).	HDAC6	is	also	known	to	regulate	autophagy	by	modulating	microtubule-dependent	delivery	of	cargo,	and	by	modulating	actin	dependent	autolysosomal	fusion	(Lee	et	al.,	2010).		The	interaction	between	LRRK2	and	HDAC6	prompted	us	to	test	whether	HDAC6	contributes	to	the	regulation	of	autophagy	by	LRRK2.	Consistent	with	previous	reports,	over-expressing	LRRK2	increased	levels	of	p62	and	LC3	in	HEK	293	cells	when	expressed	in	the	presence	of	the	lysosomal	inhibitor	bafilomycin,	which	prevents	degradation	of	p62	and	LC3	(Fig.	2.5	A).		Interestingly,	over-expressing	LRRK2	with	HDAC6	counteracted	the	changes	in	LC3	and	p62,	which	raises	the	possibility	that	the	two	proteins	can	act	in	opposition	towards	autophagy	while	both	stimulating	tubulin	deacetylation.	To	determine	whether	HDAC6	was	required	for	the	actions	of	LRRK2	on	the	autophagic	system,	we	used	siRNA	to	knockdown	HDAC6	and	examined	autophagic	vesicles	using	an	LC3:mCherry	reporter.	Immunoblots	of	cells	treated	with	HDAC6	or	scrambled	siRNA	showed	strong	decreases	in	HDAC6	with	the	HDAC6	but	not	the	scrambled	siRNA	(Fig.	2.5	B).		Having	validated	the	HDAC6	knockdown,	we	examined	the	size	of	autophagic	vesicles	in	SH-SY5Y	cells	expressing	LC3:mCherry	and	LRRK2	(WT,	G2019S	or	R1441C)	that	were	co-treated	with	HDAC6	or	scrambled	siRNA.	Prior	studies	show	that	G2019S	LRRK2	produced	large	autolysosomal	vesicles,	suggesting	autophagic	dysfunction	(Plowey	et	al.,	2008).	Consistent	with	prior	reports	over-expressing	G2019S	and	R1441C	LRRK2,	but	not	WT	LRRK2,	
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produced	significantly	larger	LC3	positive	vesicles	(Fig.	2.5	C-G).	Knockdown	of	HDAC6	prevented	the	increases	in	vesicular	size	observed	with	expression	of	mutant	LRRK2	(G2019S	or	R1441C),	but	did	not	affect	WT	LRRK2	or	vector	transfected	cells	(Fig.	2.5	C,	H--K).	These	results	suggest	that	the	presence	of	HDAC6	is	required	for	autophagic	dysfunction	mediated	by	mutant	LRRK2,	and	is	consistent	with	the	studies	from	Figure	2.4	showing	similar	activities	for	HDAC6	and	LRRK2.	These	results	also	raise	the	possibility	that	mutant	LRRK2	is	more	sensitive	than	WT	LRRK2	to	HDAC6	function.		
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Figure	2.5.	LRRK2	and	HDAC6	regulate	autophagy.	(A)	Immunoblot	showing	LRRK2	increases	the	accumulation	of	LC3	and	p62	in	the	presence	of	bafilomycin	(200	nM)	for	3	hrs;	this	is	partially	prevented	by	co-expression	of	LRRK2	with	HDAC6.	Experiments	used	the	same	lysates	as	Figure	2.4.	(B)	Immunoblot	demonstrating	HDAC6	knockdown	with	siRNA	for	HDAC6,	but	not	scrambled	siRNA	(C-K).	Knockdown	of	HDAC6	via	RNAi	versus	control	in	SH-SY5Ys	show	diminished	AV	size	in	G2019S	and	R1441C	transfected	cells.	There	is	no	significant	change	in	control	plasmid	or	WT	LRRK2	transfected	cells	when	HDAC6	is	knocked	down.	LC3-RFP-GFP	used	as	a	reporter.	(*	p<0.05,	**	p<0.01).	Scale	bar,	15	µm.	(Immunoblot	run	by	Diane	Chan	and	Nava	Zaarur.)		 	
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HDAC6	interacts	LRRK2	to	modulate	dopamine	neuronal	survival	and	neurite	
extension	To	test	whether	HDAC6	is	required	for	LRRK2	activity	on	neuronal	survival	in	
vivo,	we	utilized	the	lines	of	C.	elegans	that	we	generated	that	express	human	LRRK2	(Saha	et	al.,	2009).	Expressing	WT	LRRK2	in	these	lines	protects	dopaminergic	neurons	against	rotenone-induced	neurotoxicity	(Saha	et	al.,	2009).	To	investigate	whether	HDAC6	was	required	for	the	protection,	the	wlzIs2	line	over-expressing	WT	LRRK2	was	crossed	with	line	hda-6	(ok3203),	in	which	hda-6	(the	C.	elegans	ortholog	of	HDAC6)	is	deleted.		Each	line	was	exposed	to	rotenone	(250	nM,	24	hrs),	and	survival	of	dopaminergic	neurons	quantified.	Deletion	of	hda-6	abrogated	DA	neuron	protection	by	LRRK2	(Fig.	2.6	A-B).		As	controls,	we	also	examined	DA	neuron	survival	of	C.	elegans	line	carrying	hda-6	(ok3203)	alone,	lrk-1	km17	(a	line	carrying	a	deletion	in	the	lrk-1	gene)	alone,	as	well	as	a	cross	carrying	the	lrk-1	(km17)/hda-6	(ok3203)	deletions.	None	of	these	genetic	changes	appeared	to	modify	DA	neuron	survival	(Fig.	2.6	A-B).	These	data	suggest	that	HDAC6	is	required	for	the	actions	of	LRRK2	in	dopaminergic	neurons	using	a	simple	in	vivo	system.		 	
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Figure	2.6.	Deletion	of	hda6	significantly	reduced	DA	neuron	survival.	(A)	Deletion	of	hda6	significantly	reduced	DA	neuron	survival	in	the	WT	LRRK2/	1::GFP/rrf3(pk1426)	line,	but	had	no	effect	on	the	km-17	line.	(B)	Representative	images	of	dopaminergic	neurons	in	C.	elegans	expressing	Dat::GFP/snb::LRRK2	and	Dat::GFP/snb::LRRK2/hda-6(ok3203).	Scale	bar,	40	µm.	(Work	done	by	Shamol	Saha	and	Vivek	Gowda.)		 	
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Discussion	The	large	literature	on	LRRK2	points	to	strong	roles	for	the	protein	in	vesicular	dynamics,	synaptic	function,	cytoskeletal	processes	(neurite	extension),	translation	and	autophagy	(Saha	et	al.,	2015,	Orenstein	et	al.,	2013,	Plowey	et	al.,	2008,	Di	et	al.,	2012).		Among	the	many	functions	identified	for	LRRK2,	a	putative	role	in	regulating	tubulin	acetylation	represents	a	potentially	important	action	whose	mechanism	is	poorly	understood	(Law	et	al.,	2014).	We	recently	developed	a	regulatory	network	that	provides	a	useful	mechanism	for	understanding	the	biological	roles	of	LRRK2	or	other	genes	in	the	context	of	transcriptome	changes	associated	with	PD	(Dusonchet	et	al.,	2014).		In	the	current	report,	we	have	applied	this	systems	biology	tool	to	investigate	a	potential	mechanism	mediating	the	actions	of	LRRK2	on	tubulin	acetylation	and	autophagy.	The	histone	deacetylase,	HDAC6,	is	one	of	the	most	prominent	cytoplasmic	deacetylases,	and	has	been	shown	to	regulate	both	tubulin	acetylation	and	autophagy	(Lee	et	al.,	2010,	Haggarty	et	al.,	2003,	Pandey	et	al.,	2007).	We	observed	that	HDAC6	was	one	of	the	genes	in	our	network	that	shared	the	greatest	number	of	links	with	LRRK2,	which	highlighted	a	potentially	strong	physiological	link	between	the	two	proteins	The	studies	above	show	that	LRRK2	binds	to	HDAC6,	phosphorylates	HDAC6	and	requires	HDAC6	to	regulate	autophagy,	tubulin	acetylation	and	survival	of	dopaminergic	neurons.	HDAC6	is	the	principle	protein	known	to	modulate	tubulin	acetylation,	which	then	regulates	trafficking	of	many	different	species	along	
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microtubules	(Haggarty	et	al.,	2003).	The	interaction	of	LRRK2	with	HDAC6	provides	a	potential	mechanism	through	which	LRRK2	regulates	tubulin	acetylation	(Law	et	al.,	2014).	We	observed	that	LRRK2	acts	additively	with	HDAC6	to	reduce	tubulin	acetylation.	This	result	is	consistent	with	that	of	Law,	et	al,	who	showed	that	LRRK2	knockout	leads	to	increased	tubulin	acetylation	(Law	et	al.,	2014).	Studies	of	LRRK2	carrying	disease-linked	mutations	showed	that	mutant	LRRK2	binds	to	HDAC6,	and	failed	to	show	any	effect	on	tubulin	acetylation	that	was	consistent	across	the	varied	mutations.	The	absence	of	mutation-dependent	effects	suggests	that	tubulin	is	not	the	primary	pathway	through	which	LRRK2	causes	dysfunction	linked	to	PD.		Interestingly,	actin	was	a	primary	neighbor	of	both	LRRK2	and	HDAC6.	The	central	role	of	actin	suggests	that	the	two	proteins	strongly	interact	to	regulate	the	cytoskeleton,	and	point	to	actin,	rather	than	tubulin,	as	the	primary	target	of	LRRK2	actions.	This	observation	is	consistent	with	prior	work	from	our	and	other	groups	showing	that	LRRK2	regulates	the	actin-based	cytoskeletal	function,	and	is	considered	below	(Dusonchet	et	al.,	2014,	Chan	et	al.,	2011,	Habig	et	al.,	2013,	Caesar	et	al.,	2015).		Future	studies	will	need	to	address	whether	LRRK2	modulates	actin	acetylation	in	an	HDAC6-dependent	manner.	A	growing	consensus	points	to	autolysosomal	dysfunction	as	a	central	player	in	PD	(Wang	et	al.,	22014).	Our	results	concur	with	prior	studies.	The	regulatory	network	shows	multiple	transcripts	linked	to	autophagy	whose	levels	are	altered	in	concert	with	that	of	LRRK2	and	whose	expression	is	required	for	the	actions	of	LRRK2	in	C.	elegans;	these	transcripts	include	unc-51,	vps-34	(VPS34,	PIK3C3),	vps-
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33.1,	hda-6	(HDAC6),	ctns-1,	num-1,	and	unc-57	(Dusonchet	et	al.,	2014).	Conversely,	the	genes	linked	to	autophagy	and	vesicular	dynamics,	including	vps-34,	hda-6	and	unc-57,	require	the	presence	of	lrk-1	(the	C.	elegans	ortholog	of	LRRK2)	to	modify	DA	neuron	survival	(Dusonchet	et	al.,	2014).	These	results	suggest	that	LRRK2	plays	a	pivotal	role	in	regulating	autophagy	and	vesicular	dynamics.	Multiple	studies	also	indicate	that	disease-linked	LRRK2	mutations	cause	autolysosomal	dysfunction	(Saha	et	al.,	2015,	Orenstein	et	al.,	2013,	Plowey	et	al.,	2008).		Our	studies	concur	with	these	studies,	demonstrating	autolyosomal	dysfunction	associated	with	expression	of	G2019S	or	R1441C	LRRK2.		The	requirement	of	HDAC6	for	the	effects	of	mutant	LRRK2	in	autophagy	point	to	the	importance	of	HDAC6	in	LRRK2	biology,	but	highlight	nuanced	differences	between	the	mechanisms	of	action	between	WT	and	mutant	LRRK2.	A	“gain	of	function”	model	suggests	that	the	requirement	of	HDAC6	for	the	autolysosomal	dysfunction	induced	by	mutant	LRRK2	arises	from	increased	activity	in	a	pathway	mediated	by	HDAC6.	Our	data	does	not	rule	out	an	alternative	“loss	of	function”	model,	in	which	WT	LRRK2	could	modulate	autophagy	through	multiple	pathways,	allowing	it	to	compensate	for	HDAC6	knockdown.	In	this	model,	mutant	LRRK2	would	modulate	autophagy	only	through	a	pathway	mediated	by	HDAC6,	making	it	dependent	on	HDAC6	function	for	the	effects	on	autophagy.			Prior	studies	show	that	HDAC6	promotes	delivery	of	cargo	to	the	autolysosome,	and	autolysosomal	fusion	(Lee	et	al.,	2010).	LRRK2	stimulates	LC3	phosphorylation,	which	inhibits	LC3	function,	increasing	autolyosomal	size	(Cherra	
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et	al.,	2010).		Our	results	parallel	the	LC3	studies,	suggesting	that	LRRK2	promotes	HDAC6	phosphorylation.	These	results	suggest	that	LRRK2	acts	as	a	complex	with	HDAC6,	with	HDAC6	promoting	formation	of	autolysosomes	and	mutant	LRRK2	promoting	consolidation	to	large	autolysosomes.		The	intimate	link	between	LRRK2	and	HDAC6	is	supported	by	analysis	of	the	HDAC6	regulatory	network	derived	from	the	PD-based	transcriptomes.	41	out	of	43	(95%)	HDAC6	first	neighbors	are	in	the	LRRK2	regulatory	network.		Within	the	LRRK2	regulatory	network,	actin	exhibits	among	the	strongest	network	connection	to	HDAC6,	sharing	41	primary	or	secondary	neighbors;	only	actin	and	FZD1	(a	WNT	protein)	share	more	neighbors	in	common	(55	and	77,	respectively).	The	other	LRRK2	first	neighbors	share	between	1-33	linked	transcripts	(Dusonchet	et	al.,	2014).	HDAC6	is	known	to	regulate	actin	by	deacetylating	cortactin,	which	modulates	actin-dependent	remodeling	and	autolysosomal	fusion	(Lein	et	al.,	2007,	Gao	et	al.,	2007).	LRRK2	also	appears	to	regulate	both	microtubules,	and	actin	(Law	et	al.,	2014,	Dachsel	et	al.,	2010,	Mutez	et	al.,	2011).			 The	roles	of	HDAC6	in	LRRK2	action	provide	potentially	important	insights	into	the	pathophysiology	of	PD.		The	increased	dependence	of	disease-linked	mutations	on	HDAC6	highlights	a	putative	role	for	the	HDAC6	complex	in	the	mechanism	of	LRRK2-mediated	PD,	although	the	mechanism	is	clearly	not	a	simple	loss	of	deacetylase	activity.	In	families	with	disease-linked	mutations	in	LRRK2,	disruption	of	the	balance	among	LRRK2	functions	might	lead	to	misregulation	of	cytoskeletal	function,	neurite	outgrowth	and	autophagy,	as	observed	above	and	by	
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others	(Plowey	et	al.,	2008).	The	focus	on	HDAC6	is	consistent	with	studies	by	Law	et	al.	and	Kett	et	al.	showing	that	disease-linked	mutations	in	LRRK2	alter	binding	to	microtubules	(Law	et	al.,	2014,	Dachsel	et	al.,	2010,	Kett	et	al.,	2011),	which	is	a	known	target	of	HDAC6	function.	These	studies,	along	with	binding	to	FADD,	are	the	only	studies	showing	consistent	inhibition	of	interaction	with	LRRK2	by	a	broad	group	of	disease-linked	mutations	(Law	et	al.,	2014,	Dachsel	et	al.,	Ho	et	al.,	2009).		In	contrast	LRRK2	does	not	show	consistent	effects	of	disease-linked	mutations,	including	binding	to	proteins,	such	as	14-3-3	(YWHAQ),	RAC1,	MOESIN	or	MKK6,	and	processes,	such	as	kinase	activity	or	translational	control	(Gehrke	et	al.,	2010,	Chan	et	al.,	2011,	Nichols	et	al.,	2010,	Jaleel	et	al.,	2007,	Hsu	et	al.,	2010,	Greggio	et	al.,	2009).	The	increased	HDAC6	phosphorylation	in	postmortem	specimens	of	sporadic	PD	brain	suggests	an	involvement	of	HDAC6	in	the	pathophysiology	of	sporadic	PD.		Phosphorylation	of	HDAC6	is	thought	to	regulate	trafficking	of	cargo,	which	would	be	consistent	with	a	need	to	deliver	aggregated	proteins	and	damaged	mitochondria	for	autophagy	(Chen	et	al.	2010,	Deribe	et	al.,	2009).	Increased	phosphorylation	could	reflect	either	increased	activity	of	LRRK2	or	other	kinases	known	to	phosphorylate	HDAC6	into	the	complex.	In	this	model,	LRRK2	might	function	to	promote	consolidation	of	autolysosomal	cargo	to	form	large	inclusions,	such	as	Lewy	bodies,	which	are	the	classic	hallmark	of	PD.	Thus,	interaction	of	LRRK2	with	HDAC6	provides	compelling	mechanisms	through	which	LRRK2	might	contribute	to	the	pathophysiology	of	PD,	implicating	the	actions	of	both	kinase	and	GTPase	
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functions,	while	lending	a	possible	key	to	regulating	these	mechanisms	through	HDAC6
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CHAPTER	THREE	–	DIFFERENTIAL	REGULATION	OF	RNA-BINDING	PROTEINS	
IN	PARKINSON’S	DISEASE	REGULATED	BY	AUTOPHAGY	 	
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Introduction	This	study	highlights	the	potential	importance	of	stress	granule	formation	in	PD,	and	points	to	putative	pathophysiological	changes	in	PD	and	PD-like	diseased	brains.		Stress	granule	formation	has	emerged	in	the	field	of	neurodegeneration	as	a	compelling	mechanism	tightly	correlated	with	diseased	states.	This	study	outlines	the	pathophysiology	of	neuronal	changes	in	RBPs	in	PD,	and	elucidates	autophagy	as	the	potential	mechanism	tied	to	the	notable	lack	of	stress	granules	in	PD.	Previous	work	in	our	lab	has	expounded	on	the	importance	of	the	RNA-binding	protein,	TIA-1	in	the	misfolding	and	aggregation	of	tau	protein,	a	major	pathological	species	in	Alzheimer’s	Disease.	This	led	us	to	examine	the	localization	and	expression	of	choice	RBPs	in	PD.	The	purpose	of	this	study	is	to	begin	understanding	how	RBPs	localize	in	a	PD	spectrum	of	diseased	brains,	and	to	illuminate	the	potential	of	RBPs	as	future	therapeutic	targets	or	tools	for	early	detection.		Our	data	suggests	that	the	changes	seen	in	diseased	brains	are	not	the	result	of	αsyn	pathology,	but	the	result	of	a	dysfunction	in	an	overactive	autophagic	system	that	may	jointly	be	an	important	target	for	this	disease.		 	
Methods	
Transfections	
BE-M17	neuroblastoma	cells	were	grown	in	F12	DMEM	(ThermoFisher),	10%	FBS,	1%	Pen-Strep	and	1%	non-essential	amino	acids	and	passaged	at	80%	
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confluence.	They	were	plated	on	18	mm	poly-D-lysine	coated	coverslips	(150,000	cells/well).	Transfection	was	implemented	two	days	after	plating	when	cells	were	70%	confluent.	Cells	were	transfected	with	Lipofectamine	2000	in	OptiMEM	(Invitrogen)	as	per	the	manufactures	instructions	(Invitrogen)	at	a	ratio	of	1	µg/2.6	
µL.	LC3-RFP-GFP	was	transfected	with	other	plasmids	at	ratios	lower	than	0.5	to	ensure	uptake	of	plasmids	(ex.	transfection:	0.2	µg	LC3	+	0.8	µg	WT	LRRK2).	Cells	were	fixed	48	hours	after	transfection	in	4%	PFA	before	mounting	on	slides	with	Prolong-Gold	anti-fade	reagent	with	DAPI	(Invitrogen).	
			
Drug	treatments	Cells	were	dosed	in	culture	the	day	after	transfection.	Rapamycin	was	given	at	a	dose	of	25	nM,	50	nM	and	100	nM	concentrations.	Arsenite	was	given	at	a	concentration	of	15	µM.	Cells	were	treated	for	24	hours	before	fixation.		
	
Tissue	sections	Human	cingulate	cortex	from	the	Trojanowski	lab	were	received	NBF	fixed	and	paraffin	embedded.	Blinded	to	the	disease	status	of	the	slides,	they	were	from	age-matched	PD,	Dementia	with	Lewy	bodies	(DLB),	Parkinson’s	disease	with	dementia	(PDD),	and	control	patients	(N=6	per	condition)	(Table	3.1).	We	also	examined	tissue	from	M83	transgenic	mice	(B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J),	either	old	or	young	(N=6),	expressing	the	mutant	human	A53T	gene	(Giasson	et	al.,	2002).	 	
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	Table	3.1.	Cingulate	cortex	samples	received	from	the	University	of	Pennsylvania	tissue	bank.	PMI,	postmortem	interval	(hours)	 	
INDDID Sex AgeatDeath Clinical.DX PMI113818 65 Normal 19100786 61 Normal 6117504 59 Normal 18113695 59 Normal 13112806 46 Normal 12103590 42 Normal 16101431 M 68 DLB 15105391 F 81 DLB109329 M 68 DLB 12100061 M 73 DLB 14101577 M 76 DLB 19116793 M 72 DLB 9113669 M 70 PDD 7101337 F 91 PDD 22107509 M 75 PDD 14116441 M 82 PDD 24106857 M 79 PDD 6105386 M 74 PDD 12113383 M 82 PD 8112779 M 81 PD 7113274 M 82 PD 7113710 M 86 PD 22107878 M 78 PD 14109892 F 77 PD 3.5
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Immunohistochemistry	Performed	as	previously	described	by	our	lab	(Vanderweyde	et	al.,	2012),	Tri-sodium	citrate	antigen	retrieval	and	0.2%	Triton-X100	was	used	for	permeation.	The	slices	were	blocked	for	an	hour	with	5%	donkey	serum	in	PBS.	Incubation	of	primary	antibody	took	place	overnight	in	5%	donkey	serum	in	PBS.	Secondary	antibodies	were	applied	at	a	1:700	in	PBS	for	an	hour	and	were	respectively	Dylight488	and	Dylight543.	This	was	followed	by	TBS-T	washes	with	a	DAPI	wash.	Slides	were	than	incubated	in	1%	Sudan	Black	with	70%	ethanol	for	5	minutes.	Washes	were	performed	and	slides	were	mounted	using	Prolong-Gold	anti-fade	reagent	(Invitrogen).	Antibodies	used:	HuR	(1:300,	Santa	Cruz	Biotechnology),	G3BP	(1:300,	Becton	Dickinson,	611126),	HuC/HuD	(1:200,	Invitrogen,	A-21271),	αsyn	(1:300,	BD	transduction),	TTP	(1:300,	Santa	Cruz	Biotechnology,	sc-14030)	and	TIA-1	(1:300,	Santa	Cruz,	sc-1751).		
Immunoblot	PD	and	control	cortex	was	received	from	the	Myer’s	lab	(Table	3.2).	Brains	were	homogenized	in	RIPA	buffer	with	phosphatase	and	protease	inhibitors.	Samples	were	then	passed	through	a	22-gauge	syringe	and	left	to	rotate	overnight	at	4C.	Samples	were	then	spun	down	at	10,000	rpm	for	15	min.	Supernatant	was	analyzed	to	determine	protein	quantification	via	BCA.	Western	blot	was	preformed	as	previously	described	(Chan	et	al.,	2011,	Liu-Yesucevitz	et	al.,	2010).	Membranes	were	blocked	in	5%	milk	and	TBS-T	for	one	hour	before	primary	antibody	
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incubation	overnight.	TIA-1	(abcam,	ab40693)	was	used	at	1:1000	in	TBS-T	with	5%	BSA.	HuD	(Santa	Cruz,	sc-28299)	was	used	at	1:1000	in	PBS.	HRP-conjugated	secondary	(JacksonImmuno)	was	applied	at	1:10,000	in	PBS	for	one	hr.		
	Table	3.2.	Cingulate	cortex	samples	received	from	the	Arizona	brain	bank.	All	patients	were	male,	and	those	with	PD	displayed	no	AD	comorbidity.			 	
Patient Diagnosis Sex PMI Age	at	Death02-18 Parkinson's M 4.00 7402-37 Parkinson's M 2.00 8503-48 Parkinson's M 3.00 9005-26 Parkinson's M 7.00 7306-06 Parkinson's M 4.00 8198-38 Parkinson's M 1.00 6401-42 Parkinson's M 4.00 8504-15 Parkinson's M 3.00 8907-66 Parkinson's M 2.00 7508-70 Parkinson's M 2.00 7599-59 Control M 2.00 7897-19 Control M 2.00 8796-38 Control M 2.00 6907-37 Control M 6.00 8906-21 Control M 2.00 7303-15 Control M 3.00 8002-27 Control M 3.00 8695-40 Control M 2.00 7497-17 Control M 3.00 7899-14 Control M 2.00 86
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Primary	neurons	Sprague	Dawley	rat	pup	brains	were	stereoscopically	dissected	and	cultured	at	E18	by	Joon	Boon.	Cortical	neurons	were	plated	at	a	density	of	100,000	cells	per	well	on	poly-D-lysine	coated	coverslips	in	a	12-well	dish.	Neurons	were	maintained	in	media	consisting	of	Neurobasal	(Invitrogen),	B27	supplement	(2%	w/v),	L-glutamine	(500mM)	and	penicillin/streptomycin	(100	U/mL).		
	
Imaging	and	analysis	Images	were	taken	on	a	Nikon	epi-fluorescent	microscope.	For	the	human	tissue,	nine	images	were	taken	at	20x	for	each	slide	along	the	4th	and	5th	cortical	layers.	Algorithms	created	in	Imaris	quantified	the	number	of	cells	expressing	strong	nuclear	or	cytoplasmic	staining	as	dictated	by	the	experiment.	These	algorithms	were	created	in	the	cell	tab	of	the	software	using	the	flow	processes	to	set	quality,	intensity	and	size	thresholds	for	batch	processing.	This	method	was	used	for	quantification	of	TIA-1	expression	in	mouse	striatum.	ImageJ	macros	were	written	to	quantify	the	number	of	RBP	stained	nuclei	per	frame.	For	cell	culture,	experiments	were	done	in	duplicate,	three	times.	LC3	was	analyzed	by	hand	using	ImageJ	software.	Joanna	Kimszal,	blinded	to	conditions,	quantified	the	number	of	SGs	per	cell.		
	
A53T	fibrillization	
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A53T	αsyn	was	purchased	from	rPeptide.	Fibrillization	was	performed	following	Dr.	Virginia	Lee’s	protocol	(Volpicelli-Daley	et	al.,	2014)	and	handled	at	a	Biosafety	Level	2	(BSL	2).	A53T	was	left	to	fibrillize	for	seven	days,	shaking	at	1000	r.p.m.,	at	room	temperature.	Fractions	were	analyzed	by	colloidal	blue	staining,	and	western	blots	against	αsyn.		Dilutions	and	sonication	was	performed	as	per	the	specified	protocol.	Cortical	neurons	were	treated	once	at	DIV	7	with	freshly	sonicated	A53T	at	1:50.	50%	of	the	media	was	changed	every	7	days,	for	14	days.	On	day	13	they	were	treated	with	15	μM	arsenite.	On	day	14	neurons	were	fixed	in	4%	PFA.		
	
Statistics	Statistical	analysis	was	carried	out	with	ANOVA’s	or	Student’s	t-test	when	appropriate.	Tukey’s	post	hoc	test	was	run	in	parallel	to	calculate	significant	differences	(InStat	GraphPad	and	Prism).	Standard	errors	were	calculated	and	a	p-value	of	p	<	0.05	was	used	to	determine	significance	throughout	the	project.		 	
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Results	
Translocation	of	RBPs	from	the	nucleus	to	the	cytoplasm	in	PD	cortex	Previous	work	in	our	lab	identified	striking	formation	of	specific	RBPs	into	SGs	in	AD	brains	(Vanderweyde	et	al.,	2012).	This	informed	our	approach	to	identifying	the	pathology	of	RBPs	in	PD.	To	form	an	understanding	of	how	specific	RBPs	localize	in	PD,	and	PD-spectrum	brains	compared	to	controls,	immunohistochemistry	(IHC)	was	performed	in	cingulate	cortex	from	subjects	with	PD,	DLB,	PDD,	and	control	patients.	TIA-1	showed	strong	staining	in	the	nucleus	of	control	patients	along	the	4th	and	5th	cortical	layers.	Imaging	of	diseased	brains	showed	weaker	staining	in	the	nucleus	compared	to	control	patients.	And	the	TIA-1	appeared	to	translocate	into	the	cytoplasm	in	diseased	brains.	Our	data	suggest	that	TIA-1	exhibits	changes	in	localization	throughout	the	cingulate	cortex	of	PD,	DLB	Analysis	of	TIA-1	in	diseased	brains	shows	movement	of	TIA-1	from	the	nucleus	to	the	cytoplasm	throughout	cortical	neurons	(Figure	3.1	A-B).	While	translocation	is	visible,	it	is	possible	that	expression	levels	of	TIA-1	are	reduced	in	diseased	brains.	Immunoblots	of	PD	and	control	brains	were	run	and	analyzed.	While	the	immunoblot	was	not	significant,	there	is	a	strong	trend	towards	a	reduction	in	the	levels	of	TIA-1	in	PD	brains	compared	to	control.	Tissue	sections	were	stained	for	a	number	of	SG	markers	(TIA-1,	TTP,	HuD,	HuR	and	G3BP.).	Our	findings	with	TIA-1	mirrors	the	translocation	seen	in	AD	brains	(Vanderweyde	et	al.,	2012).	However,	unlike	AD	brains,	we	do	not	readily	see	colocalization	of	TIA-1	and	tau	in	diseased	
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brains.	Staining	of	DLB	cortex	shows	high	levels	of	tau,	and	occasional	colocalization	of	TIA-1	(Figure	3.2).		We	next	examined	HuD	due	to	its	association	with	PD	age	at	onset	(Noureddine	et	al.,	2005).	HuD,	which	normally	localizes	to	the	cytoplasm	showed	significantly	higher	levels	in	the	cytoplasm	in	PD	versus	control	cortex	(Figure	3.3	A-B).	This	finding	of	cytoplasmic	HuD	levels	that	was	observed	only	in	PD	brains	can	be	explained	based	on	the	genetic	link	of	HuD	to	PD	(Noureddine	et	al.,	2005).	Imaging	studies	suggest	that	cytoplasmic	HuD	is	increased	in	PD.	We	proceeded	to	analyze	levels	of	HuD	by	immunoblot	to	determine	whether	such	changes	could	be	accounted	for	by	changes	in	total	HuD	levels.	However,	immublots	of	HuD	in	the	cortical	lysates	did	not	show	significant	disease-linked	differences	(Figure	3.3	C).	The	absence	of	differences	in	total	HuD	levels	suggests	that	the	increased	cytoplasmic	HuD	reflected	a	change	in	the	cytoplasmic	versus	nuclear	distribution.	We	also	examined	whether	Lewy	bodies	colocalized	with	HuD,	possibly	in	a	similar	manner	to	the	way	Tau	and	TIA-1	colocalize	in	AD	brains.	But	this	was	not	observed	with	HuD	or	any	of	the	other	RBPs	throughout	the	cortices	(Figure	3.3	A,	TIA-1,	TTP,	HuR,	G3BP	are	not	shown).		We	similarly	examined	TTP,	G3BP	and	HuR.	These	RBPs	showed	no	localization	changes	in	disease	compared	to	control	cortex	(Figure	3.4).	TTP	seemed	generically	localized	to	cytoplasm	and	nucleus	throughout	the	cortices.	G3BP	widely	varied	throughout	individual	cortices,	localizing	to	both	cytoplasm	and	nucleus.	HuR	showed	a	trend	towards	nuclear	localization	in	PD	brains.	What	is	of	great	
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significance	from	our	examination	of	these	RBPs	in	diseased	brains	is	the	unexpected	lack	of	SGs	in	these	PD	cortices.	This	is	largely	different	from	AD	in	which	significant	increases	in	SG	formation	are	seen	(Vanderweyde	et	al.,	2012,	supplemental,	Figure	3.1	A).	This	study	highlights	the	potential	importance	of	a	loss	of	SG	formation	in	PD,	and	points	to	putative	pathophysiological	changes	in	PD	and	PD-like	diseased	brains.			 	
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Figure	3.1.	TIA-1	translocates	from	the	nucleus	to	the	cytoplasm	in	diseased	brains.	(A)	IHC	on	human	cingulate	cortex	from	postmortem	PD	and	PD-like,	AD	and	control	patients.	Sections	were	stained	for	TIA-1	(red)	and	DAPI	(blue).	Analysis	was	performed	blinded.	White	arrows	indicate	SGs.	Scale	bar,	10	μm.	(B)	A	significant	decrease	in	nuclear	TIA-1	was	observed	in	diseased	brains	compared	to	control	brains	(*p	<	.001)	(C)	Immunoblot	of	TIA-1	from	4	PD	and	5	control	cingulate	cortices	indicates	that	TIA-1	expression	levels	do	not	significantly	change.	Student’s	t-tests	were	performed	for	analysis	in	Prism.		
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Figure	3.2.	DLB	cingulate	cortex	shows	some	colocalization	of	tau	and	αsyn	with	TIA-1.	(A)	IHC	on	DLB	cingulate	cortex	shows	some	colocalization	of	tau	(CP13)	and	TIA-1.	White	arrows	show	colocalization	while	yellow	arrows	show	no	colocalization	of	TIA-1	and	tau.	(B)	IHC	on	DLB	cingulate	cortex	shows	weak	colocalization	of	αsyn	and	TIA-1.	Yellow	arrows	indicate	slight	colocalization	of	TIA-1	with	Lewy	bodies.	Scale	bar,	20	μm.	 	
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Figure	3.3.	HuD	exhibits	higher	levels	of	cytoplasm	localization	in	PD.	(A)	IHC	on	human	cingulate	cortex	from	postmortem	PD	and	PD-like,	and	control	patients.	HuD	exhibits	higher	levels	of	cytoplasm	localization	in	PD.	Sections	were	stained	for	HuD	(green),	αsyn	(red)	and	DAPI	(blue).	Analysis	was	performed	blinded.	White	arrows	indicate	Lewy	bodies	which	did	not	colocalize	with	HuD.	Scale	bar,	10	μm.	(B)	A	significantly	higher	level	of	HuD	was	observed	in	PD	cortex	compared	to	DLB,	PDD	and	control	brains	(*p	<	.001)	(C)	Immunoblot	of	HuD	from	4	PD	and	5	control	cingulate	cortices	indicates	that	HuD	expression	levels	do	not	significantly	change.	A	one-way	ANOVA	and	student’s	t-test	were	performed	for	analysis	in	Prism.			
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Figure	3.4.	TTP	and	G3BP	show	no	noticeable	change	in	localization	from	the	nucleus	to	the	cytoplasm	in	PD,	PDD	and	DLB	brains	versus	control.	HuR	trends	towards	a	nuclear	return	in	diseased	brains.	Staining	of	TTP,	G3BP	and	HuR	in	diseased	(PD,	PDD,	DLB)	and	control	cortex.	Arrows	indicate	cytoplasmic	staining.	Scale	bar,	10	μm.		
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αsyn	does	not	modify	TIA-1	localization	The	low	levels	of	TIA-1	positive	SGs	in	PD	brains	led	us	to	examine	the	mechanism	behind	the	lack	of	SGs	in	PD.	We	hypothesized	that	this	loss	was	due	to	a	disruption	in	formation	of	SGs	by	αsyn	or	by	a	dysfunction	in	autophagy,	two	attributes	associated	specifically	with	PD.	To	determine	whether	changes	in	localization	of	RBPs	were	αsyn	dependent,	tissue	was	examined	from	young	and	old	A53T	mice	and	compared	them	to	control	mice.	These	mice	constitutively	express	the	human	mutant	A53T	under	direction	of	the	mouse	prion	promoter,	with	high	expression	levels	seen	in	the	striatum	(Giasson	et	al.,	2002).	No	changes	in	TIA-1	were	observed	between	old	A53T	expressing	mice	and	control	mice	(Figure	3.5).	There	was	a	small	decrease	in	TIA1-positive	nuclei	in	young	A53T	mice.		Old	A53T	mice	did	not	show	the	same	decrease,	exhibiting	no	statistically	significant	decrease	in	TIA-1	positive	nuclei.	This	suggests	that	αsyn	does	not	cause	an	age-dependent	shift	in	TIA-1	localization.	The	data	presented	above	suggest	that	αsyn	over-expression	does	not	affect	the	distribution	of	TIA-1,	a	principle	SG	protein	that	is	known	to	exhibit	changes	in	distribution	in	tauopathies	and	ALS	(Liu-Yesucevitz	et	al.,	2010,	Vanderweyde	et	al.,	2012).		With	no	observable	changes	in	an	aged	αsyn	mouse	model	of	PD,	we	continued	our	exploration	by	moving	into	human	cell	culture	to	further	parse	whether	the	lack	of	SGs	was	αsyn	dependent.			 	
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Figure	3.5.	TIA-1	shows	no	localization	changes	in	old	A53T	mice.	TIA-1	staining	in	mouse	striatum	from	control,	young	and	old	A53T	mice.	Scale	bar,	25	μm.	Quantification	of	nuclei	was	preformed	via	an	algorithm	created	in	IMARIS	software.	There	is	a	small	significant	difference	between	control	and	young	A53T	mice.	A	one-way	ANOVA	was	performed	for	analysis	in	Prism	(p	<	.05).			 	
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αsyn	does	not	effect	SG	formation	To	further	explore	whether	αsyn	mediates	the	SG	pathway,	we	compared	the	effects	of	transfecting	WT	αsyn	versus	A53T	αsyn	on	TIA-1-RFP	expression	in	BE-M17	cells.	BE-M17	cells	were	transfected	with	a	control	plasmid,	WT	αsyn	or	A53T	along	with	TIA-1-RFP	as	a	read	out	of	SG	formation.	The	number	of	SGs	were	counted	per	cell.	While	SGs	were	abundant	due	to	the	overexpression	of	transfecting	in	TIA-1-RFP,	there	was	no	observable	difference	in	the	number	of	SGs	between	WT	αsyn	or	A53T	αsyn	(Figure	3.6	A-B).	There	was	a	slight	increase	in	the	number	of	SGs	quantified	in	WT	αsyn	transfected	cells	compared	to	both	control	and	A53T	transfected	cells,	but	this	result	was	not	significant.	There	were	no	differences	between	the	mutant	αsyn	and	control.	This	is	not	a	wholly	surprising	finding	since	other	groups	have	debated	the	efficacy	of	transfection	αsyn	into	cells	as	a	model	of	a	PD-like	diseased	state;	while	others	have	shown	that	αsyn	transfection	does	not	readily	cause	aggregation	in	cell	culture	(Giasson	et	al.,	2002,	Nonaka	et	al.,	2011,	Tsika	et	al.,	2014).	There	is	similarly	some	controversy	in	the	literature	regarding	the	extent	to	which	transgenic	mice	over-expressing	αsyn	exhibit	oligimerization	and	aggregation	similar	to	that	observed	in	PD	(Giasson	et	al.,	2002).	Increasing	evidence	suggests	that	exposing	neurons	to	exogenous	pre-formed	αsyn	fibrils	can	elicit	neurodegeneration	associated	with	the	accumulation	of	intracellular	αsyn	aggregates	(Volpicelli-Daley	et	al.,	2014).		Based	on	the	aforementioned	body	of	evidence	supporting	treatment	of	neurons	to	fibrillized	αsyn,	we	looked	into	the	effects	of	the	fibrillization	prone	
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A53T	mutation	on	SG	count.	This	mutation	was	chosen	as	apposed	to	WT	αsyn	due	to	its	propensity	to	aggregate	as	well	as	its	genetic	correlation	with	early	onset	PD	(Clayton	et	al.,	1999,	Giasson	et	al.,	2002).	A53T	peptide	was	purchased	from	rPeptide	and	induced	to	fibrilize.	Virginia	Lee’s	protocol	to	induce	fibrillized	αsyn	was	followed	in	detail	(Volpicelli-Daley	et	al.,	2014).	A53T	peptide	was	left	shaking	at	room	temperature	for	seven	days.	Fibrils	were	assessed	via	colloidal	blue	staining.	Sonication	was	preformed	immediately	before	use.	Using	rat	cortical	neurons	from	E18	pups,	they	were	treated	once	on	DIV	7	with	fibrillized	and	freshly	sonicated	A53T	for	14	days.	Fibrillized	αsyn	is	robust	after	a	single	treatment	left	for	14	days	(Figure	3.7).	On	day	13	of	αsyn	treatment,	neurons	were	treated	with	arsenite	to	induce	SG	formation.	While	fibril	expression	was	robust	in	neuronal	culture,	and	SGs	observable	by	ICC	after	arsenite	treatment,	no	change	was	seen	in	the	number	of	SGs	formed	between	fibril	and	non-treated	neurons	(Figure	3.6	C-D).	Based	on	our	studies	of	A53T	overexpressing	mice,	and	fibrillized	A53T	treatment	of	neuronal	culture	showing	no	difference	in	the	number	of	TIA-1	positive	SGs	we	concluded	that	αsyn	is	not	the	mechanism	by	which	SGs	are	downregulated	in	PD.			 	
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Figure	3.6.	A53T	does	not	effect	SG	formation.	(A)	BE-M17	cells	transfected	with	either	backbone,	WT	αsyn	or	A53T	and	TIA-RFP	plasmid.	White	arrows	indicate	SGs.	Cells	were	treated	with15	μM	arsenite.		Scale	bar,	7	μm.	(B)	No	significant	difference	in	SG	count	was	observed.	(C)	Rat	cortical	neurons	treated	were	treated	with	fibrillized	and	sonicated	αsyn	for	14	days.	On	day	13	they	were	treated	with	15	μM	arsenite.	White	arrows	indicated	SGs.	Scale	bar,	7	μm.	(D)	No	significant	difference	in	SG	count	was	observed.	A	one-way	ANOVA	and	student’s	t-test	were	performed	for	analysis	in	Prism.	
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Figure	3.7.	Recombinant	A53T	fibrils.	Rat	cortical	neurons	were	treated	once	with	fibrillized	and	freshly	sonicated	A53T	on	DIV	7.	50%	of	the	media	was	changed	every	7	days.	ICC	shows	large	amounts	of	phosphorylated	αsyn	present	after	14	days.	White	arrows	indicate	phosphorylated-αsyn	(red)	staining,	DAPI	is	in	blue.	Scale	bar,	50	μm.	
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Co-regulation	of	autophagy	and	SGs	in-vitro	Based	on	the	relatively	new	findings	of	regulation	between	RBPs	and	autophagy	(Buchan	et	al.,	2013,	Seguin	et	al.,	2014,	Kim	et	al.,	2014),	it	seemed	probable	that	an	upregulation	of	autophagy	in	PD	was	causative	of	the	low	levels	of	SGs	we	observed	in	PD.	Transfection	of	TIA-1-RFP	into	BE-M17	cells	was	a	useful	way	to	establish	a	baseline	of	the	effect	of	autophagy	on	SGs.	Through	the	use	of	24-hour	rapamycin	treatment,	an	mTOR	inhibitor	that	enhances	autophagy,	a	decrease	was	observed	in	the	size	of	SGs,	which	was	quantified	by	ImageJ	analysis	(Figure	3.8).	This	result	is	similar	to	that	of	Parker’s	group	in	which	they	also	saw	a	decrease	in	number	of	SGs	upon	stimulation	of	autophagy,	indicating	a	breakdown	of	SGs	by	autophagy	(Buchan	et	al.,	2013).	Transfections	with	TIA-1	and	LC3-RFP-GFP	were	carried	out	to	elucidate	whether	RBPs	effect	autophagosome	formation.	Arsenite	was	used	to	stress	the	cells.	Our	results	showed	that	while	both	TIA-1	and	arsenite	increase	the	size	of	autophagosomes,	arsenite,	and	particularly	arsenite	plus	TIA-1	significantly	increased	the	number	of	autophagosomes.	This	finding	identifies	a	regulation	of	autophagy	by	TIA-1	in	a	stressed	state	(Figure	3.9).	This	is	of	particular	interest	because	it	suggests	a	mounting	regulation	of	RBPs	and	autophagy	as	a	diseased	state	progresses,	potentially	leading	to	the	deregulation	of	the	overactive	autophagy	pathway	seen	in	PD	brains,	as	well	as	the	lack	of	SGs.			These	data	suggest	that	αsyn	is	not	the	cause	of	a	loss	of	SGs	in	PD,	but	that	the	pathophysiology	of	PD,	associated	with	a	dysfunction	of	the	SG	pathway,	is	related	to	dysfunctions	in	an	upregulated	autophagic	system.		
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Figure	3.8.	SG	size	was	significantly	decreased	upon	activation	of	autophagy	suggesting	that	autophagy	breaks	down	SGs	or	regulates	their	formation.	A	one-way	ANOVA	was	performed	for	analysis	in	Prism	(p<.001).	Scale	bar,	5	μm.	SGs	were	quantified	by	hand	using	ImageJ	software.	BE-M17	cells	transfected	with	TIA-RFP	treated	with	varying	concentrations	of	rapamycin	or	ethanol.	SGs	indicated	by	white	arrows.		
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Figure	3.9.	TIA-1	and	arsenite	enhance	the	size	of	autophagosomes.	Transfections	with	TIA-1	and	LC3-RFP-GFP	were	implemented	to	determine	whether	RBPs	effect	autophagosomal	formation.	While	both	TIA-1	and	arsenite	enhance	the	size	of	autophagosomes,	arsenite,	and	particularly	arsenite	plus	TIA-1	significantly	increased	the	size	of	autophagosomes,	indicating	a	regulation	of	autophagy	by	SG	markers	in	a	stressed	state.	A	one-way	ANOVA	was	performed	for	analysis	in	Prism	(p<.001).	Scale	bar,	5	μm.	Autophagosomes	indicated	by	white	arrows.		 	
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Discussion	Our	study	begins	to	elucidate	the	relationship	of	RBPs	in	PD.	Prior	to	this	study,	the	pathology	of	RBPs	in	PD	had	yet	to	be	investigated.	As	we	began	to	study	this	connection	though	analysis	of	PD	and	PD-like	brains,	we	discovered	a	surprising	lack	of	SGs	in	the	PD	biology.	Previous	work	in	our	lab	examined	the	biology	of	RBPs	in	AD	(Vanderweyde	et	al.,	2012).	That	work	similarly	found	large	differences	in	RBPs	throughout	the	disease	life	cycle.	TIA-1,	TTP	and	G3BP	showed	the	largest	differences,	with	translocation	to	the	cytoplasm,	large	stress	granules	and,	in	the	case	of	TIA-1,	colocalization	with	Tau.	That	study	spurred	our	interest	in	examining	RBPs	in	PD	and	whether	the	same	RBPs	would	show	similar	changes	in	PD.	Our	findings	in	PD	and	related	diseases	differed	significantly	from	that	observed	in	AD.	Translocation	was	observed	from	the	nucleus	to	the	cytoplasm	with	TIA-1	and	HuD,	but	not	with	G3BP	and	TTP,	indicating	a	differential	regulation	of	RBPs	among	different	diseases.		There	are	over	800	RBPs	and	a	corresponding	flexibility	of	biological	responses	by	RBPs.	Although	the	response	of	TIA-1	SGs	is	muted	in	PD,	our	study	found	significant	changes	in	the	localization	of	HuD,	which	is	a	mostly	cytoplasmic	RBP	that	exhibits	an	even	higher	ratio	of	cytoplasmic	to	nuclear	localization	in	PD.	This	was	particularly	interesting	since	HuD	has	been	linked	to	age-at-onset	in	PD	(Noureddine	et	al.,	2015).	HuD,	also	known	as	ELAVL4,	is	a	neural	specific	RBP	that	binds	U-rich	regulatory	elements	in	3’-UTRs	of	mRNAs.	It	is	integral	in	inhibiting	mRNA	rapid	turnover	through	the	binding	of	these	U-rich	regions,	and	has	been	
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shown	specifically	to	bind	tau	mRNA	and	regulate	its	expression	levels	(Aranda-Abreu	et	al.,	1999).	Tau,	a	microtubule-associated	protein	is	genetically	linked	to	PD,	and	second	only	to	αsyn	in	attributable	risk	percentage	for	PD	(Lei	et	al.,	2010).	PD	patients	with	the	A53T	mutation	also	display	increased	tau	pathology	(Irwin	et	al.,	2013).	And	both	tau	and	αsyn	cross-seed	fibrillization	(Giasson	et	al.,	2003).	The	study	by	Aranda-Abreu	shows	that	knockdown	of	HuD	leads	to	a	decrease	in	the	levels	of	tau	(Aranda-Abreu	et	al.,	1999).	Our	study	reveals	HuD’s	increased	translocation	from	the	nucleus	to	the	cytoplasm	in	PD	compared	to	control	brains	with	no	change	in	expression	levels.	HuD	localizes	mainly	to	the	cytoplasm	(Kasashima	et	al.,	1999),	but	this	enhanced	expression	in	the	cytoplasm	could	indicate	an	over-activity	of	HuD	in	PD.	It	is	important	to	determine	whether	this	enhanced	expression	in	the	cytoplasm	correlates	with	expression	level	changes	of	tau,	especially	since	the	translocation	was	not	seen	as	strongly	in	PDD	and	DLB	brains.	The	strong	link	between	tau,	HuD	and	αsyn	present	an	important	link	that	could	lead	to	targeted	regulation	of	the	disease.		TIA-1	showed	the	strongest	translocation	from	the	nucleus	to	the	cytoplasm	in	diseased	brains.	However,	the	lack	of	TIA-1	positive	SGs	was	surprising	given	the	strong	formation	seen	in	AD	brains.	Examining	levels	of	TIA-1	in	PD	compared	to	age-matched	controls	revealed	no	significant	differences,	although	there	was	a	trend	towards	reduced	TIA-1	levels	in	PD	brains.	Decreased	levels	of	TIA-1	could	explain	the	lower	levels	of	SGs	in	PD	but	it	wouldn’t	account	for	the	absence	of	SGs	from	the	other	RBPs	(i.e.	HuD	which	maintained	steady	expression	levels	and	has	also	been	
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shown	to	form	stress	granules	in	response	to	stressors	such	as	heat	shock)	(Burry	et	al.,	2006).		A	decreased	level	of	SGs	could	reflect	either	decreased	production	or	increased	removal	of	SGs.	Although	the	mechanism	of	such	changes	is	currently	unclear,	the	prominence	of	αsyn	in	the	pathophysiology	of	PD	raises	the	possibility	that	the	accumulation	of	αsyn	contributes	to	the	reduced	SG	response.	This	led	us	to	examine	whether	the	lack	of	SGs	was	due	to	a	disruption	by	αsyn,	the	hallmark	protein	aggregate	in	the	pathology	of	PD,	or	to	autophagy,	the	cellular	mechanism	of	PD	shown	to	be	dysregulated.	Our	findings	showed	no	regulation	of	SG	biology	by	αsyn,	but	strong	mutual	regulation	of	autophagy	and	SGs.		Autophagy	and	RBPs	recently	have	emerged	in	the	field	of	neurodegeneration	as	possible	correlates	with	co-regulation	in	the	formation	of	SGs	and	autophagosomes.	Autophagy	appears	to	play	an	integral	role	in	SG	turnover	(Buchan	et	al.,	2013).	Valocin	containing	protein	(VCP)	plays	a	pivotal	role	in	linking	SGs	with	autophagy.	VCP	is	a	disaggregase	that	can	disperse	SGs;	knockdown	of	VCP	greatly	increased	SGs	throughout	HeLa	cells,	presumably	due	to	reduced	SG	turnover	(Buchan	et	al.,	2013,	Seguin	et	al.,	2014).	Mutations	in	VCP	cause	frontotemporal	lobar	degeneration,	with	associated	deficits	in	autophagy.	Another	group	outlined	the	regulation	of	HuD	over	autophagy	via	binding	to	the	3’-UTR	of	Atg5	mRNA	(Kim	et	al.,	2013).	They	showed	that	knockdown	of	HuD	decreased	Atg5	levels,	while	overexpressing	it	enhanced	those	levels,	leading	to	increased	autophagy.	This,	along	with	mutant	LRRK2,	could	provide	another	mechanism	
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accounting	for	increases	in	the	activity	of	some	autophagic	pathways	in	PD,	perhaps	as	a	compensatory	response	to	dysfunction	caused	by	αsyn	aggregation	in	other	pathways.	Strong	HuD	translocation	into	the	cytoplasm	would	potentially	upregulate	some	autophagic	pathways,	which	would	cause	a	reciprocal	reduction	in	the	levels	of	SGs	in	PD.	This	tight	regulation	between	RBPs	and	autophagy	could	be	a	potential	target	for	correcting	autophagic	dysfunction	in	PD.			The	prominent	role	of	αsyn	in	the	pathophysiology	of	PD	led	us	to	hypothesize	that	dysfunction	in	the	SG	pathway	might	be	caused	by	αsyn.	Previous	work	in	our	lab	demonstrated	strong	co-localization	of	TIA-1-positive	SGs	with	tau	in	AD	brains	(Vanderweyde	et	al.,	2012).	Since	tau	has	been	show	to	seed	the	fibrillization	of	αsyn	(Giasson	et	al.,	2015),	and	αsyn	is	the	pathologic	protein	of	fibrillization	in	PD,	we	were	interested	in	examining	whether	αsyn	played	a	role	in	regulating	TIA-1-postitive	SG	formation.	However,	multiple	independent	approaches	failed	to	show	a	demonstrable	effect	of	αsyn	on	SGs,	and	no	co-localization	of	Lewy	bodies	and	RBPs	was	observed.		Autophagy	is	regulated	by	multiple	intersecting	pathways.	Previous	studies	indicate	that	SG	levels	are	modulated	by	autophagy.	Our	studies	concur	with	the	published	literature	(Kim	et	al.,	2013).	Treatment	with	rapamycin,	which	increases	autophagy,	robustly	reduced	SG	levels.	αsyn	is	classically	thought	to	decrease	autophagy	in	the	PD	brain,	however	the	autophagic	response	might	be	more	nuanced	than	a	simple	on	or	off	response.	Compensatory	changes	in	the	autophagic	
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pathways	in	PD	could	possibly	reduce	the	SG	response,	producing	the	results	described	above.	Our	study	examines	the	interaction	between	SGs	and	autophagy	through	a	cell	culture	lens.	Activating	autophagy	led	to	a	decrease	in	SG	size	delineating	either	a	break	down	of	SGs	or	a	disruption	in	this	process.	Live	cell	imaging	should	be	conducted	to	differentiate	this	change.	Conversely,	overexpressing	TIA-1	under	conditions	of	stress	resulted	in	an	increase	in	the	number	of	autophagosomes.	This	novel	observation	of	co-regulation	provides	a	potentially	new	target	to	the	field	in	regulating	the	homeostasis	of	SGs	and	autophagy.		A	few	studies	have	shown	that	αsyn	is	degraded	by	autophagy	(Lee	et	al.,	2004,	Riedel	et	al.,	2010),	while	others	show	that	it	might	inhibit	autophagy	(Winslow	et	al.,	2010).	This	connection	needs	to	be	further	clarified,	since	both	αsyn	and	autophagy	are	deregulated	in	PD.	Our	study	shows	that	αsyn	does	not	effect	SG	formation,	but	that	autophagy	and	the	SG	pathway	are	important	mechanisms	for	co-regulation	of	these	two	processes	that	diverge	in	diseased	states.	As	further	studies	on	this	association	continue,	there	may	yet	be	a	connection	between	some	RBPs	and	αsyn.	HuD	is	a	prime	candidate	for	this	continued	exploration	due	to	it’s	influences	in	PD.	This	study	expounds	on	the	relationship	of	SGs	and	autophagy	in	PD.	Moving	forward,	regulating	these	pathways	may	be	an	important	innovation	in	the	field.			
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CHAPTER	FOUR	–	CONCLUSION		 	
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This	body	of	work	highlights	a	novel	connection	between	PD-associated	innervation	of	autophagy,	and	the	pathogenesis	of	SGs	in	PD.	We	hypothesized	that	HDAC6	and	LRRK2	interact	to	regulate	autophagy,	and	determined	that	PD-associated	LRRK2	mutations	require	HDAC6	for	its	regulation	of	autophagy.	We	further	hypothesized	that	the	pathophysiology	of	PD	leads	to	differential	expression	and	localization	of	RBPs	implicated	in	the	SG	response.	Differential	expression	was	observed	with	TIA-1	and	HuD	in	PD	brains,	as	were	notably	low	levels	of	SGs.	This	lack	of	SG	is	likely	the	result	of	a	co-regulation	of	the	autophagy	pathway	and	SG	response.	Our	challenge	is	to	tie	these	findings	into	a	singular	mechanism	by	which	disease	progression	may	be	halted.		PD	is	a	wide-spread	endemic	with	all	pharmacological	interventions	since	the	50s	focused	solely	on	targeting	dopamine	in	the	CNS.	Current	therapeutics	combat	this	dysregulation	by	flooding	the	CNS	with	dopamine.	This	is	a	quick	fix,	and	does	nothing	to	combat	the	underlying	cause	of	the	disease.	fWith	a	growing	population	of	elderly	people,	the	occurrence	of	PD	will	continue	to	rise.	The	above	studies	highlight	potentially	new	targets	in	this	field	that	could	lead	to	wholly	new	therapeutics.		Genomics	research	in	the	field	has	identified	LRRK2	as	an	important	correlate	to	disease	progression	with	the	G2019S	mutation	present	in	5-6%	of	familial	cases	and	1-2%	of	sporadic	cases	(Li	et	al.,	2014).	Based	on	the	relevance	of	LRRK2	in	PD,	revealing	the	LRRK2	regulatory	network	allows	for	greater	understanding	of	associated	transcripts	and	their	functions.	HDAC6,	as	the	most	
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closely	linked	in	our	network	to	PD,	defines	an	exciting	connection	between	LRRK2	and	HDAC6	in	PD,	and	autophagy,	the	bridge	between	them.	LRRK2	and	HDAC6	have	both	been	shown	to	enhance	autophagy	at	the	initiation	and	autophagolysosomal	fusion	stage	(Plowey	et	al.,	2008,	Lee	et	al.,	2010).	Our	finding	defines	a	potential	mechanism	by	which	this	might	occur.	Phosphorylation	of	HDAC6	by	LRRK2	could	enhance	the	deacetylase	activity	of	HDAC6	since	other	substrates	that	phosphorylate	HDAC6	have	been	shown	to	enhance	its	deacetylase	activity	(Du	et	al.,	2015).	This	enhanced	deacetylase	activity	could	therein	lead	to	its	enhanced	control	over	the	fusion	of	the	autophagosome	to	the	lysosome,	and	perhaps	an	upregulation	of	this	stage	in	autophagy.	It	would	be	interesting	to	examine	whether	the	LRRK2-HDAC6	complex	at	the	fusion	stage	of	autophagy	binds	with	increased	propensity	when	LRRK2	mutations	are	present.	Our	finding	of	actin	as	a	first	neighbor	of	LRRK2	and	HDAC6	is	especially	poignant	since	HDAC6	increases	autophagosome-lysosomal	fusion	through	recruitment	of	an	F-actin	network.	And	deacetylation	activity	within	this	network	is	essential	for	fusion	(Lee	et	al.,	2010).	With	increased	kinase	activity	in	LRRK2	mutants,	upregulating	autophagic	formation,	as	well	as	enhancing	HDAC6	deacetylase	activity	as	trends	from	our	study	show,	it	is	conceivable	that	overactivation	through	this	pathway	leads	to	the	dysregulation	of	autophagy	seen	in	PD.	Inhibiting	HDAC6	in	this	overactive	pathway	may	be	a	promising	target	in	PD.		In	AD	autophagy	is	disrupted.	One	group	found	AD	associated	mutations	disrupt	autophagic	flux,	while	another	found	autophagic	proteins	to	be	
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downregulated	in	AD	(Orr	et	al.,	2013).		A	study	by	Wolfe	et	al.,	2013	outlines	the	failure	of	lysosomal	degradation	of	materials	due	to	poor	buffering	and	high	pH	(Wolfe	et	al.,	2013).	These	autophagic	dysfunctions	differ	from	PD	in	which	increased	lysosomal	acidity	is	observed	upon	overexpression	of	the	G2019S	mutation	(Henry	et	al.,	2015).	While	this	group	found	lysosomes	to	have	a	low	pH	upon	overexpression	of	mutant	LRRK2	their	findings	on	the	degradative	capacity	of	the	lysosome	was	conflicting.	Other	PD	associated	mutations	do	lead	to	dysfunctional	lysosomes	such	as	mutations	in	ATP13A2	and	GBA.	ATP13A2	is	a	transmembrane	lysosomal	ATPase	that	expresses	mainly	in	the	brain	(Yang	et	al.,	2014).	PD	associated	mutations	in	this	gene	lead	to	reduced	degradative	properties	of	the	lysosome	(Dehay	et	al.,	2013).	Mutations	in	the	lysosomal	enzyme	glucocerebrosidase	(GBA)	lead	to	the	lysosomal	storage	disorder,	Gaucher’s	disease.	Heterozygous	mutations	of	this	gene	have	also	been	correlated	with	PD,	but	are	more	closely	related	to	DLB	(Irwin	et	al.,	2014).	GBA	mutations	associated	with	PD	lead	to	an	accumulation	of	glucosylceramide	in	the	lysosome	(Dehay	et	al.,	2013).	This	is	an	interesting	finding	because	it	points	to	another	potential	overload	of	the	autophagic	system.	As	seen	in	prionogenic	diseases,	prions	can	accumulate	in	the	lysosome	blocking	its	ability	to	degrade	other	cargo	(Whatley	et	al.,	2008).	This	study	also	found	an	efflux	of	prions	via	exosomes	due	to	an	inability	of	the	lysosome	to	degrade	these	stable	proteins.	αsyn,	also	shown	to	have	prionogenic	properties	(Giasson	et	al.,	2002),	may	block	degradation	of	lysosomal	cargo	via	a	similar	build-up.	It	would	be	interesting	to	determine	whether	exosomal	release	of	αsyn	fibrils	
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happens	via	a	similar	mechanism.		The	difference	in	autolysosomal	function	in	PD	and	AD	are	important	findings	not	only	because	they	vary	from	PD-associated	autolysosomal	dysfunction,	but	because	they	vary	in	a	way	that	highlights	the	mechanistic	differences	we	see	with	RBPS	in	PD.	Our	findings	of	differential	regulation	of	certain	RBPs	and	a	disrupted	SG	pathway	in	PD	is	exciting	because	it	highlights	a	novel	mechanism	and	target	of	dysregulation	in	PD	that	hadn’t	been	previously	considered.	Strong	TIA-1	positive	SG	in	AD	brains	led	us	to	examine	whether	these	SGs	were	present	in	PD.	However,	they	were	not	present.	Upon	further	evaluation	this	could	be	a	differential	regulation	by	autophagy.	As	mentioned	above,	many	of	the	mutations	and	correlates	of	AD	lead	to	a	downregulation	of	autophagy.	Whereas,	in	PD,	many	of	the	mutations	and	processes	lead	to	an	enhancement	of	this	pathway	at	the	initiation	and	fusion	stage,	particularly	the	G2019S	and	R1441C	mutations	(Plowey	et	al.,	2008,	Bravo-San	Pedro	et	al.,	2012).	Even	αsyn	leads	to	an	upregulation	of	autophagy	via	inhibition	of	CMA	.	One	group	found	that	WT	αsyn	overexpression	leads	to	oligomers	that	cannot	use	CMA.	Any	blockage	of	CMA	leads	to	an	upregulation	of	autophagy,	as	the	group	found	by	further	studying	the	A53T	mutation	which	tightly	bound	LAMP-2A	receptors	but	failed	to	cross	the	lysosomal	membrane,	inevitably	blocking	CMA,	inhibiting	it	and	leading	to	a	compensatory	increase	in	autophagy	(Day	et	al.,	2012).				 Strong	expression	of	HuD	in	PD	cytoplasm	may	be	another	mechanism	by	which	autophagic	initiation	is	upregulated.	As	mentioned	above,	a	group	found	HuD	
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binds	the	3’	end	of	atg5	mRNA,	preventing	its	degradation	and	upregulating	its	expression	levels	(Kim	et	al.,	2014).	They	further	found	that	inhibiting	autophagy	with	3MA	or	baflomycin	lead	to	an	increase	in	autophagy.	This	parallels	the	levels	of	SGs	we	see	in	AD	and	PD.	Paired	with	the	knowledge	that	HuD	is	associated	with	age	at	onset	of	PD,	our	findings	hint	to	a	prime	target	for	downregulating	autophagic	induction	in	PD.			 There	remains	a	wealth	of	information	to	be	captured	on	the	dysregulation	of	autophagy	in	neurodegenerative	disease.	Cuervo’s	group	highlights	an	important	distinction	between	quality	control	autophagy	and	starvation	induced	autophagy,	while	pointing	out	that	the	mechanistic	differences	between	these	disparate	inductions	is	unknown	(Cuervo	et	al.,	2007).	HDAC6	is	the	first	protein	to	be	shown	to	play	a	role	in	only	one	of	these	two	separate	pathways,	as	HDAC6	played	no	role	in	starvation	induced	autophagy	(Cuervo	et	al.,	2007).	This	makes	HDAC6	another	prime	candidate	for	regulation	of	autophagy	since	quality	control	autophagy	is	the	main	form	of	autophagy	in	the	brain.	Other	tissues	rely	largely	on	starvation	induced	autophagy	(Mizushima	et	al.,	2003).	HDAC6	is	also	present	in	SGs	and	may	be	integral	for	targeting	them	to	aggresomes	for	degradation	(Seguin	et	al.,	2014).	A	few	groups	have	shown	the	reciprocal	relationship	between	valosin	containing	protein	(VCP)	and	HDAC6	(Boyault	et	al.,	2007,	Seguin	et	al.,	2014).	VCP	is	an	ubiquitin	selective	chaperone	and	ATPase	that	is	also	important	for	autophagic	flux	(Seguin	et	al.,	2014).	High	VCP	over	HDAC6	levels	causes	HDAC6	unbiding	from	ubiquitin	and	decreased	degradation	of	formerly	bound	targets	(Boyault	et	al.,	
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2007).	It	would	be	interesting	to	test	whether	HDAC6	modulates	SG	ubiquitination,	and	whether	upregulating	levels	of	VCP	might	reverse	any	enhanced	degradation	by	HDAC6,	especially	since	VCP	has	been	shown	to	be	important	for	autophagic	degradation	of	SGs	(Buchan	et	al.,	2013).			 While	αsyn	showed	no	effect	on	SG	formation	in	our	hands,	future	studies	should	further	explicate	the	importance	of	this	protein	in	the	autophagic-RBP	pathway.	A	finding	by	Nilsson	et	al.,	2013	presented	a	novel	finding	on	autophagy	in	AD	(Nilsson	et	al.,	2013).	This	group	found	that	autophagy	secretes	abeta	from	cells	allowing	for	the	formation	of	extracellular	plaques.	Whereas	mice	with	KO	in	atg	genes	showed	no	extracellular	plaques.	This	is	an	incredible	finding	because	it	highlights	the	importance	of	tightly	regulating	autophagy.	Whether	autophagy	secretes	amyloid	beta	under	normal	conditions	or	does	this	as	a	compensatory	mechanism	against	lysosmal	dysfunction	in	AD,	this	is	a	finding	that	needs	to	be	replicated	in	PD.	Again,	if	αsyn	is	similarly	transported	out	of	cells,	this	could	be	the	mechanism	by	which	fibrils	are	seeded	throughout	the	brain.	It	could	point	to	another	potentially	benefit	of	downregulating	autophagy	in	PD.	Enhancing	lysosomal	function	as	a	way	of	unburdening	the	insult	of	disease-linked	upregulation	of	autophagic	initiation	and	flux	could	be	another	beneficial	target	in	PD.	However,	dopamine	neurons	are	already	energetically	stressed,	and	downregulating	an	overactive	stage	of	autophagic	flux	would	be	a	safer	target.						 Our	findings	highlight	a	novel	pathway	in	which	autophagic	dysfunction	is	exacerbated	in	PD	(Figure	4.1).	Multiple	PD-associated	mutations	including	the	
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A53T,	G2019S	and	R1441C	mutations	lead	to	an	upregulation	of	the	initiation	and	the	fusion	stage	of	autophagy	that	leads	to	dysregulation	in	disease.	The	SG	pathway	also	leads	to	upregulation	of	autophagy	and	subsequent	breakdown	of	SGs.	HuD	and	HDAC6	are	two	important	proteins	in	this	process	that	similarly	lead	to	upregulation	of	autophagy.	Future	studies	and	therapeutics	should	look	to	these	two	proteins	as	a	way	of	downregulating	autophagy	and	potentially	abating	the	progression	of	pathology	in	PD.		 	
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Figure	4.1.	Dysregulation	of	autophagy	in	PD.	αsyn	blocks	CMA	via	irreversible	binding	to	LAMP-2A,	which	prevents	other	proteins	from	crossing	into	the	lysosome.	Loss	of	αsyn	degradation	by	CMA	leads	to	cytoplasmic	accumulation	of	
αsyn	monomers	and	subsequent	oligomerization.	Inhibition	of	CMA	leads	to	compensatory	upregulation	of	autophagic	initiation,	and	degradation	of	αsyn	by	autophagy.	High	levels	of	αsyn	leads	to	cellular	stress	and	translocation	and	TIA-1	into	the	cytoplasm	where	it	forms	SGs.	HuD,	localized	to	the	cytoplasm,	also	increases	autophagic	initiation	by	stabilizing	mRNA	and	increasing	expression	of	autophagy	dependent	proteins	such	as	atg5.	Mutant	LRRK2	complexes	with	HDAC6,	leading	to	the	hyperphosphorylation	of	HDAC6,	and	its	enhanced	deacetylase	activity.	This	complex	enhances	fusion	of	the	autophagosome	to	the	lysosome.	p-HDAC6,	present	in	SGs,	may	also	enhance	targeting	of	SGs	for	degradation.	Over-activity	of	this	pathway	may	lead	to	ATP	depletion	and	cellular	dysfunction	due	to	the	overwhelming	ATP	burden	required	by	the	lysosome	(adapted	from	Lynch-Day	et	al.,	2012).			
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